



US009139833B2

(12) **United States Patent**  
**Han et al.**

(10) **Patent No.:** US 9,139,833 B2  
(45) **Date of Patent:** \*Sep. 22, 2015

(54) **MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE**(71) Applicant: **Arrowhead Research Corporation**, Pasadena, CA (US)(72) Inventors: **Jang Han**, Lafayette, CA (US); **Mi-Young Seo**, Berkeley, CA (US); **Michael Houghton**, Danville, CA (US)(73) Assignee: **Arrowhead Research Corporation**, Pasadena, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/796,606**(22) Filed: **Mar. 12, 2013**(65) **Prior Publication Data**

US 2014/0073683 A1 Mar. 13, 2014

**Related U.S. Application Data**

(62) Division of application No. 10/626,879, filed on Jul. 25, 2003, now abandoned.

(60) Provisional application No. 60/470,230, filed on May 14, 2003, provisional application No. 60/461,838, filed on Apr. 11, 2003, provisional application No. 60/398,605, filed on Jul. 26, 2002.

(51) **Int. Cl.**

<b>C12N 15/11</b>	(2006.01)
<b>C12N 15/113</b>	(2010.01)
<b>A61K 31/711</b>	(2006.01)
<b>A61K 38/00</b>	(2006.01)

(52) **U.S. Cl.**

CPC .....	<b>C12N 15/113I</b> (2013.01); <b>A61K 31/711</b> (2013.01); <b>A61K 38/00</b> (2013.01); <b>C12N 2310/111</b> (2013.01); <b>C12N 2310/14</b> (2013.01); <b>C12N 2310/322</b> (2013.01); <b>C12N 2310/334</b> (2013.01); <b>C12N 2310/335</b> (2013.01); <b>C12N 2310/3515</b> (2013.01); <b>C12N 2310/53</b> (2013.01)
-----------	---

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,610,054 A	3/1997	Draper
5,624,803 A	4/1997	Noonberg et al.
5,801,154 A	9/1998	Baracchini et al.
5,922,857 A	7/1999	Han et al.
6,001,990 A	12/1999	Wands et al.
6,063,628 A	5/2000	Loeb et al.
6,107,027 A	8/2000	Kay et al.
6,133,246 A	10/2000	McKay et al.
6,174,868 B1	1/2001	Anderson et al.
6,297,003 B1	10/2001	Rice et al.

6,297,370 B1	10/2001	Cha et al.
6,506,559 B1	1/2003	Fire et al.
7,718,632 B2	5/2010	Van Heeke et al.
2002/0019363 A1	2/2002	Ismaili et al.
2002/0086356 A1	7/2002	Tuschi et al.
2002/0155582 A1	10/2002	Lemon et al.
2003/0143732 A1	7/2003	Fosnaugh et al.
2003/0153519 A1	8/2003	Kay et al.
2003/0206887 A1	11/2003	Morrissey et al.
2003/0219823 A1	11/2003	Alsobrook et al.
2004/0192626 A1	9/2004	McSwiggen et al.
2005/0043266 A1*	2/2005	Jayasena et al. .... 514/44
2005/0209180 A1	9/2005	JadHAV et al.
2005/0255487 A1	11/2005	Khvorova et al.
2006/0211742 A1	9/2006	Leonardi et al.
2008/0113351 A1	5/2008	Naito et al.
2011/0166058 A1	7/2011	Hinkle et al.

## FOREIGN PATENT DOCUMENTS

WO	WO 93/23569 A1	11/1993
WO	WO 95/30746 A1	11/1995
WO	WO 01/90121 A2	11/2001
WO	WO 02/18404 A2	3/2002
WO	WO 02/32920 A2	4/2002
WO	WO 02/057287 A2	7/2002
WO	WO 02/057425 A2	7/2002
WO	WO 02/081494 A1	10/2002
WO	WO 02/100415 A2	12/2002
WO	WO 03/070750 A2	8/2003
WO	WO 2004/011647 A1	2/2004
WO	WO 2004/065601 A2	8/2004

## OTHER PUBLICATIONS

Czauderna et al.; "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells"; Nucleic Acids Research 31(11):2705-2716 (2003).

Dias et al.; "Antisense Oligonucleotides: Basic Concepts and Mechanisms" Mol. Cancer Ther. 1:347-355 (2002).

Doherty et al.; "Ribozyme Structures Andmechanisms" Annu. Rev. Biophys. Biomol. Struct. 30:457-475 (2001).

Dorsett et al.; "siRNAs: Applications in Functional Genomics and Potential As Therapeutics" Nature Reviews—Drug Discovery 3:318-329 (2004).

Elbashir et al.; "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells" Nature—Letters to Nature 411:494-498 (2001).

Jarczak et al.; "Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons" FEBS Journal 272:5910-5922 (2005).

(Continued)

Primary Examiner — Tracy Vivlemore

Assistant Examiner — Kate Poliakova

## (57)


**ABSTRACT**

The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA molecules that are modified to be resistant to nuclelease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer.

(56)

**References Cited****OTHER PUBLICATIONS**

- Kawasaki et al.; "World of small RNAs: from ribozymes to siRNA and miRNA" *Differentiation* 72:58-64 (2004).
- Kraynack et al.; "Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity" *RNA* 12(1):163-176 (2006).
- Kruger et al.; "Involvement of Proteasome Alpha-Subunit PSMA7 in Hepatitis C Virus Internal Ribosome Entry Site-Mediated Translation" *Molecular and Cellular Biology* 21(24):8357-8364 (2001).
- Lee et al.; "Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice" *Hepatology* 32(3):640-646 (2000).
- Lieber et al.; "Elimination of Hepatitis C Virus RNA in Infected Human Hepatocytes by Adenovirus-Mediated Expression of Ribozymes" *Journal of Virology*; 70(12):8782-8791 (1996).
- Macejak et al.; "Inhibition of Hepatitis C Virus (HCV)-RNA-Dependent Translation and Replication of a Chimeric HCV Poliovirus Using Synthetic Stabilized Ribozymes" *Hepatology* 31(3):769-776 (2000).
- Macejak et al.; "Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA" *Journal of Viral Hepatitis* 8:400-405 (2001).
- Miyagishi et al.; "Comparison of the Suppressive Effects of Antisense Oligonucleotides and siRNAs Directed Against the Same Targets in Mammalian Cells" *Antisense and Nucleic Acid Drug Development* 13:1-7 (2003).
- Ohkawa et al.; "Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro" *Journal of Hepatology* 27:78-84 (1997).
- Peracchi; "Prospects for antiviral ribozymes and deoxyribozymes" *Rev. Med. Virol.* Review 14:47-64 (2004).
- Puerta-Fernandez et al.; "Ribozymes: Recent Advances in the Development of RNA Tools" *FEMS Microbiology Reviews* 27:75-97 (2003).
- Randall et al.; "Clearance of Replicating Hepatitis C Virus Replicon RNAs in Cell Culture by Small Interfering RNAs" *PNAS* 100(1):235-240 (2003).
- Ryu et al.; "Identification of the Most Accessible Sites to Ribozymes on the Hepatitis C Virus Internal Ribosome Entry Site"; *Journal of Biochemistry and Molecular Biology*; 36(6):538-544 (2003).
- Ryu et al.; "NOTE: Comparative Analysis of Intracellular Trans-Splicing Ribozyme Activity Against Hepatitis C Virus Internal Ribosome Entry Site" *The Journal of Microbiology* 42(4):361-364 (2004).
- Sakamoto et al.; "Intracellular Cleavage of Hepatitis C Virus RNA and Inhibition of Viral Protein Translation by Hammerhead Ribozymes" *J. Clin. Invest.* 98:2720-2728 (1996).
- von Weizsacker et al.; "Gene Therapy for Chronic Viral Hepatitis: Ribozymes, Antisense Oligonucleotides, and Dominant Negative Mutants" *Hepatology—Concise Review* 26(2):251-255 (1997).
- Wang et al.; "Subsection E: Methods of RGS Protein Inhibition—[15] Ribozyme- and siRNA-Mediated Suppression of RGS-Containing RhoGEF Proteins" *Methods in Enzymology* 389:244-265 (2004).
- Welch et al.; "Ribozyme Gene Therapy for Hepatitis C Virus Infection" *Clinical and Diagnostic Virology* 10:163-171 (1998).
- Yu et al.; "Activity of HDV Ribozymes to Trans-Cleave HCV RNA" *World J. Gastroenterol.* 8(4):694-698 (2002).
- Muller-Kuller et al.; "Identification and Characterization of a Highly Efficient Anti-HIV Pol Hammerhead Ribozyme" *Oligonucleotides* 19:265-271 (2009).
- Saetrom; "Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming" *Bioinformatics* 20(17):3055-3063 (2004).
- Paul et al.; "Effective Expression of Small Interfering RNA in Human Cells" *Nature Biotech* 20:505-508 (2002).
- Elbashir et al.; "Functional anatomy of siRNAs for mediating efficient RNAi in *Drosophila melanogaster* embryo lysate" *The EMBO Journal* 20(23):6877-6888, Dec. 3, 2001.
- Opalinska et al.; "Nucleic-Ccid Therapeutics: Basic Principles and Recent Applications" *Nature Reviews Drug Discovery*, 1:503-514 (2002).
- Brach et al.; "A good antisense molecule is hard to find" *Trends in Biochemical Sciences* 23(2):45-50 (1998).
- Chirila, T.V., et al., "The use of Synthetic Polymers for Delivery of Therapeutic Antisense Oligodeoxynucleotides" *Biomaterials*, 23(2):321-342 (2002).
- Agrawal, S. et al., "Antisense therapeutics: Is It as Simple as Complementary Base Recognition?" *Molecular Med. Today* 6:72-81 (2000).
- Peracchi, A., "Prospects for Antiviral Ribozymes and Deoxyribozymes" *Reviews in Medical Virology* 14(1):47-64 Jan./Feb. (2004).
- Crooke, S.T., *Antisense Research & Appli.*, Chapter 1, pp. 1-50, Ed. by ST Crooke, Publ. by Springer-Verlag (1998).
- Lindenbach et al., "RNAi Targeting an Animal Virus: News from the Front," *Molecular Cell* 9(5):925-927 May 2002.
- Novina et al., "siRNA-Directed Inhibition of HIV-1 Infection," *Nature Medicine* 8(7):681-686, Jul. 2002.
- Seo et al., "Small Interfering RNA-Mediated Inhibition of Hepatitis C Virus Replication in the Human Hepatoma Cell Line Huh-7," *Journal of Virology*, Jan. 2003, pp. 810-812, vol. 77, No. 1, American Society for Microbiology.
- Augeri et al., "Purification, Characterization, Gene Cloning, and Expression of *Saccharomyces cerevisiae* Redoxyendonuclease, a Homolog of *Escherichia coli* Endonuclease III," *Biochemistry, American Chemical Society*, 36:721-729 (1997).
- Baker et al., "2'-O-(2-Methoxy) Ethyl-Modified Anti-Intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase The ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells," *The Journal of Biochemical Chemistry*, 272(18):11994-12000, May 2, 1997.
- Bartschslager, et al., "Sequences in the 5' Nontranslated Region of Hepatitis C Virus Required for RNA Replication," *Journal of Virology, American Society for Microbiology*, 75(24):12047-12057, Dec. 2001.
- Barton et al., "Retroviral Delivery of Small Interfering RNA Into Primary Cells," *Genetics*, 99(23):14943-14945, Nov. 12, 2002.
- Bhan et al., "2',5'-Linked Oligo-3'-Deoxyribonucleoside Phosphorothioate Chimeras: Thermal Stability and Antisense Inhibition of Gene Expression," *Nucleic Acids Research, Oxford University Press*, 25(16):3310-3317, 1997.
- Chiang et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms," *The Journal of Biological Chemistry*, 266(27):18162-18171, Sep. 25, 1991.
- Coleman et al., "Synthesis and Postsynthetic Modification of Oligodeoxynucleotides Containing 4-Thio-2'-Deoxyuridine (ds4U)," *Journal of American Chemical Society*, 116:11636-11642 (1994).
- Damba et al., "Properties of Arabinonucleic Acids (ANA & 20'F ANA): Implications for The Design of Antisense Therapeutics That Invoke RNase H Cleavage of RNA," *Nucleosides, Nucleotides & Nucleic Acids, Marcel Dekker, Inc.*, 20(4-7):429-440 (2001).
- Dector et al., "Rotavirus Gene Silencing by Small Interfering RNAs," *EMBO Reports, European Molecular Biology Organization*, 3(12):1175-1180 (2002).
- Elbashir et al., "RNA Interference is Mediated by 21 and 22-Nucleotide RNAs," *Genes & Development, Cold Spring Harbor Laboratory Press*, 15:188-200 (2001).
- Giannaris et al., "Oligoribonucleotides Containing 2',5'-Phosphodiester Linkages Exhibit Binding Selectivity for 3',5'-RNA Over 3',5'-ssDNA," *Nucleic Acids Research*, 21(20):4742-4749 (1993).
- Gil et al., "Induction of Apoptosis by The dsRNA-Dependent Protein Kinase(PKR): Mechanism of Action," *Apoptosis, Kluwer Academic Publishers*, 2000, 5(2):107-114 (2000).



286	304
siRNA <sub>5</sub>	5' - GUACUGCCUGAUAGGGUGCUU UUCAUGACGGACUAUCCCACG-5'
GL2	5' - CGUACGCGGAUACUUCGAU UUGCAUGGCCUUAUGAAGCU-5'
GL3	5' - CUAACGGUGAGUACUUCGAU UUGAAUGCGACUCAUGAAGCU-5'
SIN	5' - AUCUCUACGGUGGUCCUAU UUAGAGAUGCCACCAGGAUU-5'

FIG. 1

Fig. 2

	Domain	sequence (NN-N19-NN)	Position		
5U8	5'UTR	cc-CUGUGAGGAACUACUGUCU-uc	45-63	sense	CUGUGAGGAACUACUGUCUUC
				antisense	AGACAGUAGUUCCUCACAGGG
5U9	5'UTR	ua-CUGUCUUCACGCAGAAAGC-gu	58-76	sense	CUGUCUUCACGCAGAAAGCGU
				antisense	GCUUUCUGCGUGAAGACAGUA
5U10	Core	cg-AGACUGCUAGCCGAGUAGU-gu	244-262	sense	AGACUGCUAGCCGAGUAGUUGU
				antisense	ACUACUCGGCUAGCAGUCUCG
C1	Core	ga-AUCCUAACCUCAAAGAAA-aa	352-370	sense	AUCCUAACCUCAAAGAAAAAA
				antisense	UUUCUUUGAGGUUJAGGAUUC
C2		gg-UCAGAUCGUCGGUGGAGUJU-ua	425-443	sense	UCAGAUCGUCGGUGGAGGUUUA
				antisense	AACUCCACCGACGAUCUGACC
C3		gg-UAAGGUCAUCGAUACCCUC-ac	701-719	sense	UAAGGUCAUCGAUACCCUCAC
				antisense	GAGGGLUAUCGAUGACCUUACC
C4	NS5B	ac-GGCGUGAACUAUGAACAG-gg	822-840	sense	GGCGUGAACUAUGAACAGGG
				antisense	CUGUUGCAUAGUUCAGGCCGU
C5		cc-GGUUGCUCCUUUUCUAUCU-uc	852-870	sense	GGUUGCUCCUUUUCUAUCUUC
				antisense	AGAUAGAAAAGGAGCAACCGG
5B1		gc-UCUUCAUACGGAUUCCAAU-ac	8163-8181	sense	UCUUCAUACGGAUUCCAAUAC
				antisense	AUUGGAAUCCGUAUGAAGAGC
5B2	NS5B	ca-UACGGAUUCCAAUACUCUC-cu	8167-8187	sense	UACGGAUUCCAAUACUCUCU
				antisense	GAGAGUAUUGGAAUCCGUAUG
5B3		uu-UGACUCAACGGUCACUGAG-aa	8270-8288	sense	UGACUCAACGGUCACUGAGAA
				antisense	CUCAGUGACCGUUGAGUCAAA
5B4		cc-UUCACGGAGGCUAUGACUA-ga	8613-8631	sense	UUCACGGAGGCUAUGACUAGA
				antisense	UAGCUAUAGCCUCCGUGAAGG
5B5	NS5B	au-ACGACUUGGAGUJUGUAAC-aa	8671-8689	sense	ACGACUUGGAGUJUGUAACAU
				antisense	GUUAUCAACUCCAAGUCGUAU
5B6		au-UCCUGGUAGGCAACAUCA-uc	8817-8835	sense	UCCUGGUAGGCAACAUCAUC
				antisense	UGAUGUUGCCUAGCCAGGAAU
5B7		uu-GUGGCAAGUACCUCUCAA-cu	9160-9178	sense	GUGGCAAGUACCUCUCAACU
				antisense	UUGAAGAGGUACUUGGCCACAA
5B8		au-GUGGUGGCCUACUCCUACUU-uc	9317-9335	sense	GUGGUGGCCUACUCCUACUUUC
				antisense	AAGUAGGAGUAGGCACCAAU
3U1	3'UTR	cu-UUGGUGGUCCCAUCUUAGC-cc	9506-9524	sense	UUGGUGGUCCCAUCUUAGCCC
				antisense	GCUAAGAUGGAGCCACCAAAG
3U2		gu-CACGGCUAGCUGUGAAAGG-uc	9531-9549	sense	CACGGCUAGCUGUGAAAGGUC
				antisense	CCUUUCACAGCUAGCCGUGAC
3U3		ag-CCGCUUGACUGCAGAGAGU-gc	9558-9576	sense	CCGCUUGACUGCAGAGAGUGC
				antisense	ACUCUCUGCAGUCAAGCGGC

**FIG. 3A**

1 ttatagggtt ttacacctacc cagggaaaacg caaccaacct cgatctcttg tagatcttgt  
61 ctctaaacga actttaaaat ctgtgtactgt gtcgcctccg tgcatgcctta gtgcacccatc  
121 gcagtataaa caataataaa ttactgtc gttgacaaga aacgagaac acgtcgatc tgcctccctct  
181 tctcgacact gcttacgggtt tgcgtccgt tgcatgtcat catcagata ccttaggttcc  
241 gtccgggtgt gaccggaaagg taagatggag agcctgttc ttgggtgtcaa cgagaaaaaca  
301 cacgtccaac tcagtgttgc tgcttccgt tgtagagacg tgctagtgcg tggttccggg  
361 gactctgtgg aagaggccct atccggaggca ctgtaaaccacc taaaaaatgg cacttgtgtt  
421 ctatgtatc tgaaaaaaagg cgtactgccc cagcttgaaac accgcctatgt gttcataaaa  
481 cgttctgtatc cttaaaggcc acataccggc cacaagggtt tgacgtgtt tgccgaaaatg  
541 gacggccattc agtacggctg tagccgtata acactgggg tactctgtcc acatgtggcc  
601 gaaaccccaa ttgcataccg caatgttctt ctgcgtaaac acggtaataa gggagccgg  
661 ggtcatagct atggcatcg tctaaagct tatgacttag gtgacgacgt tggcacgtat  
721 cccattgttcaag atttataaca aaactggaaactaaagcatg gcatgtgtgc actccgtgaa  
781 ctcaactgtg agtcaatgg aggtgcacgtc actcgctatg tgacaaacaa ttctgtggc  
841 ccagatgggtt acccttcttgc ttgcataaaa gattttctg caccgcggg caagtcaatg  
901 tgactctt cogaacaact tgattacalc gagtcaagaaga gagggtctt ctgcgtccgt  
961 gaccatgtac atgaaattgc ctggtcaact gacgcgtctg ataagagctt cgagcaccag  
1021 acacccctcg aaattaagag tgccaaagaaa ttgacactt tcaaaaggaa atgccccaaag  
1081 ttgtgtttc ctcttaactc aaaagtcataa gtcattaaac cactgtttga aaagaaaaaaag  
1141 actgggggtt tcatggggcg tatacgctt gtgttccctg tgcatctcc acaggagtgt  
1201 aacaatatgc acttgcatac ctgtatggaa tgtaatcatc gcatgttgc tcatgtgc  
1261 acgtgtgtacttgcataaaggc cactgtgtaa catttggca ctggaaaattt atgtatggaa  
1321 ggacctacta catgtgggtt cctacactt aatgtgttag tgaaaalgcc atgtctgtcc  
1381 tgtaaagacc cagagatgg acctgagcat atgtgtcgat attatcacaa ccactcaaac  
1441 atggaaaactc gactccgcac gggagggtagg actagatgtt ttggaggctg tgggtttggc  
1501 tatgtggct gctataataa gcggtccatc tgggtccctc gtgtactgtc tgatattggc  
1561 tcagggccata ctggcattac tggtacaat gtggagaccc tgaatgagga tctcccttg  
1621 atactgtgtc tgtaaactgtt taacattaaac atgtgtggcg atttcattt gaatgaag  
1681 ttgtccatca ttgtgcata tttctctgtc ttcataaggc ctttattgtc cactataaaag  
1741 agtctgtt acacaatgtt caaaaccattt gtgtactgtc ggggttacta laaagtattacc  
1801 aaggaaaaggc cgttggaaacttggacaaatggacaaac agatgtactgtttaacacca  
1861 ctgtgtgtt ttcccttccataa ggctgtgtt gtatcatgat caattttgc ggcacactt  
1921 gatgcggcata accatcaatc ttcgttgggaa caaaggacgc ctgtccatc actgtatgg  
1981 atttcgttac acgtcatatcg ttcgtgtcc gccatgttta alacttcaga cctgtccatc  
2041 aacagtgtca ttattatggc atatgttaact ggtgttccatc tacaacacac ttcgtatgg  
2101 ttgtctatc ttgggcac tactgtgtaa aaactcaggc ctatcttgc atggattgg  
2161 gcaaaacttca gtcggaggat tgaatttctc aaggatgtt gggagatctt caaatttctc  
2221 attacagggtt ttgttgcata cgtcaagggtt caaatacagg ttcgttgcata taacatcaag  
2281 gattgtgtaa aatgttcatc tgcgtgtt aacaaggcactc tggaaatgtt cattgtatca  
2341 gtcactatcg ctggccaaa gtgtgtatca ctcacttagt gtgtactgtt catgtccaa  
2401 agcaaggggac ttacccgtca gtcgtatgtt gcaaggacgc agtgcacact acatgtcc  
2461 ctaaggcata caaaagaatg aaccctttctt gaaagggtt gatcatgcac agtacttacc  
2521 tctggagggtt tgcgttcaaa gaaagggtt gtcgtccatc tggacgcac tggatgttgc  
2581 ttccaaatggatcatgtt gggccacca gtcgtgttcaaa atggccatc tgcgtatlag  
2641 attaaggaca aagaacaata ctgcgtccatc ttcctgttgc ttcgttgc ttcgtatgg  
2701 ttccgttcaaa aagggggttgc accaataaa ggtgttaccc tttggagaaga tactgtttgg  
2761 qaagtcaaq gttacaqaaatggatgttgc acatgttgc gtcgtatggacq tttgtqacaaa

**FIG. 3B**

2821 gtgcttaatg aaaagtgc tgcactact gttgaatccg gtaccgaagt tactgagtt  
2881 gcatgttgt tagcagaggc tggtgtgaag actttacaac cagtttgc ttccttacc  
2941 aacatggta ttgatcttg tgagtggagt gtatgtatcatactatt tgatgtatc  
3001 ggtgaagaaa acttttcac acgtatgtat ttgccttt accctccaga tgaggaagaa  
3061 gaggacgtg cagagtgta ggaagaagaa attgtgaaat cctgtgaaca tgatgtacgt  
3121 acagaggatg attataagg ttcctctg gaatttggc ctcagctg aacagtgc  
3181 gttgaggaag aagaagggaa agactggc tgatgtatc ctgagcaatc agagatgt  
3241 ccagaaccag aacctacacc tgaagaacca gttaatcgtt ttactggta tttaaaactt  
3301 actgacaatg ttgcattaa atgttgtac atcgtaagg aggacaaaag tgtaatcct  
3361 atggtgatg taatgtgc taacatacac ctgaaacatg tggtgggtg agcagggtca  
3421 ctcacaagg caaccaatgg tgccatcaa aaggagatg atgattacat taagctaat  
3481 gccccttc ctagggagg gcttgc tttctggac ataatctgc taagaatgt  
3541 ctgcatgtt ttggactaa cttaaatgc ggtgaggaca tccagcttc taaggcagca  
3601 taatggaaaat tcattcaca ggacatcta ctgcacccat tgggtgcggc aggatattt  
3661 ggtctaaac ctttcgtt tttacaatgt tggtgcggc cggttcgatc acaggtttat  
3721 atgcgtca atgacaaatgc tttttatgtc caggatgtca tggattatct tgataaccgt  
3781 aaggcttagag tggaaagcacc taaacaagag gagccaccaa acacagaaga ttccaaaact  
3841 gaggagaaat ctgcgtaca gaaggctgc gatgtgaagc caaaaattaa ggctgcatt  
3901 gatgaggtt ccacaacact ggaagaaact aagtttcta ccaataatgtt actcttgtt  
3961 gctgatatac atggtaatgt ttaccatgt ttcagaaca tgcttagagg tgaagatgt  
4021 tttccctg agaaggatgc accttacatg tgatgtatc ttatctact tggtgatatc  
4081 acttgcgtt taatccctt caaaaaggctt ggtggcacta ctgagatgtc ctaagatgt  
4141 tggaaagaaat tgccatgtt tgatgtatata accacgttcc ctggacaagg atgtgtgt  
4201 tataacttgc atggtaatgtt gactgtctt aagaaatgc aatctgcatt ttatgtacta  
4261 ctttcagaag caccatgtc taagggaaatg atttttatgtc tttttatgtc  
4321 gaaatgtt ctatgtca agagacaaga aaatataatgc ctatgtcat ggtgttata  
4381 gccataatgg caaccatcca acgtatgtt aaagggatataa aaatcaaga gggcatcg  
4441 gactatggt tccgattttt cttttatgtt agttaatggc ctgtatgtt tattttatgt  
4501 aagctgtact ctctaaatgt ggcgtgtc acaatgc tttttatgtt gacacatgtt  
4561 ttatcttg aagaggctgc ggcgtgtatc cgatcttta aagcttcgc cgtatgtca  
4621 gtatcatcac cagatgtgt tactatcatat aatggatacc tcaatctgc atcaaaagaca  
4681 tctggggggc actttgtt aacatgttctt ttggctggctt ctatcagaga ttggccat  
4741 tcggacacgc gtatgtatgtt aggtgttggaa ttctttaatgc tggtgtacaa aatgtgtac  
4801 cacactctgg agggcccggtt cggatgttcat ctgtacgggtt aggtgttcatc actgtacaaa  
4861 cttatccctt ggggggggtt aagactataa aatgtgttcatc aactgtgggc  
4921 aacactaaatc tccacacaca gctgtggat atgtctatgc cataatggaca gcgtttgtt  
4981 ccaacataatc tggatgttgc tggatgttaca aaaaataaaatc tcaatgttgc tcatgagggt  
5041 aagacttctt tttttatgtt tttttatgtt gacacatgtt gacacatgtt  
5101 catactctgg atggatgtt tttttatgtt tttttatgtt gacacatgtt  
5161 tggaaaattt cttcaatgtt tggatgttaca tcaatgttaca gggatgttaca caattgtt  
5221 tttttatgtt tttttatgtt actttcaacatc tttcaatgttaca aatcaatgtt accaggcat  
5281 caaggggtt atttatgttgc cttgtgtgtt gatgtgttaca actttgtgtt actttatgtt  
5341 gtttacatgtt atttatgttgc tttttatgtt gatgtgttaca actttgtgtt  
5401 ctacatgtt tttttatgtt gatgtgttaca actttgtgtt  
5461 ggtcggatggat tttttatgtt gatgtgttaca actttgtgtt  
5521 tttttatgtt gatgtgttaca actttgtgtt  
5581 tttttatgtt gatgtgttaca actttgtgtt  
5641 tttttatgtt gatgtgttaca actttgtgtt  
5701 tttttatgtt gatgtgttaca actttgtgtt  
5761 tttttatgtt gatgtgttaca actttgtgtt  
5821 accatcaacgc tttttatgtt gatgtgttaca actttgtgtt  
5881 tttttatgtt gatgtgttaca actttgtgtt  
5941 ccaactcaac tttttatgtt gatgtgttaca actttgtgtt  
6001 aatgtgttaca actttgtgtt  
6061 tttttatgtt gatgtgttaca actttgtgtt  
6121 tttttatgtt gatgtgttaca actttgtgtt

FIG. 3C

6181 caggctacaa ccaagacaac gttcaaccac aacacttgg ttttgcgtg ttccatggat  
6241 acaaaggccag tagatacttc aaattcattt gaagttctgg cagtagaaga cacacaaggaa  
6301 atggacaatc ttgcgttga aagtcaacaa cccaccccttg aagaagtatg gaaaatct  
6361 accatacaga aggaagtcat agagtgtac gtggaaacta ccgaagtgt aggcaatgt  
6421 atacttaaac catcagatga aggtgttaaa gtacacacaag agtgttgc tgaggatct  
6481 atggctgtt atgtggaaaa cacaaggcatt accattaaga aacctaatacg gcttccacta  
6541 gccttaggt taaaacaat tgccacatc ggtatgtctg caataatag tgccttgg  
6601 agtaaaaattt tggcttgcattt ccaaaccatc tttaggacaaga cagaattac aacatcaat  
6661 tgccgttga gattagcaca acgtgtgtt aacaaattt tgccatgtt gtttacattt  
6721 tgttccat tttgttgcattt tactaaaatg accaattcttga attttagagc ttcaactt  
6781 aacaattatg ctaaaaatg tgtaaagggt gtgtcaaat tttttttttt tgccggcatt  
6841 aatttgcataa agtcaaccatc aattttttttt tgccatgtt tgccatataat gtttccat  
6901 ttaagtatgtt gtttgcataa tttttttttt tgccatgtt tgccatataat gtttccat  
6961 aattttgttgc ttcccttca tttttttttt tgccatgtt tgccatataat gtttccat  
7021 ttactacta tggatttctg tgaagggtt tttttttttt tgccatgtt tgccatataat  
7081 gactcccttg attttttttt tgccatataat gtttccat  
7141 cttagacttgc caattttttt tgccatataat gtttccat  
7201 aaattttttt attttttttt tgccatataat gtttccat  
7261 agtcaatttca tcagaaatcc ttggcttgc tggttttttca ttgtatgtt acaaatttgc  
7321 cccgttttttgc caatgttttttgc tggttttttgc aagtttttttgc atttttttttgc  
7381 agtcaatttgc attttttttgc tggttttttgc tggttttttgc tggttttttgc  
7441 aatctgttgc caccgtttgc tggttttttgc tggttttttgc tggttttttgc  
7501 gtttttttttgc aatggggggcc ttggcttgc aagtttttttgc atttttttttgc  
7561 gacacatttttgc acgttttttgc tggttttttgc tggttttttgc tggttttttgc  
7621 ctttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
7681 tggttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
7741 catccgttgc cccatttttgc caattttttgc aatttttttgc tggttttttgc tggttttttgc  
7801 ctggccatttttgc attttttttgc tggttttttgc tggttttttgc tggttttttgc  
7861 ttttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
7921 ctgtatgttgc acgttttttgc tggttttttgc tggttttttgc tggttttttgc  
7981 gacacccatttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8041 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8101 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8161 aaacttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8221 accttataataat gtttttttttgc tggttttttgc tggttttttgc tggttttttgc  
8281 gcaaggccatc tcaatgttgc tggttttttgc tggttttttgc tggttttttgc  
8341 aaagacttacatc ttttttttttgc tggttttttgc tggttttttgc tggttttttgc  
8401 aacaacatc ttttttttttgc tggttttttgc tggttttttgc tggttttttgc  
8461 acttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8521 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8581 ttgttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8641 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8701 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8761 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8821 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8881 tggttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
8941 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9001 acttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9061 ttgttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9121 gtttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9181 atttttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9241 gggttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9301 caaccccttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9361 ttgttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9421 catgttttttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc  
9481 ccaccccttgc tggttttttgc tggttttttgc tggttttttgc tggttttttgc

FIG. 3D

**FIG. 3E**

12901 aacctaaata gaggtatggc gctggggcagt tttagtgcata cagtagcttc tcaggctgg  
12961 aatgcacag aagttacccgc caattcaact gtgtttccct tctgtgttgc tgcaatgc  
13021 cctgctaaag catalaaggga ttacccatcg aagttggggc aaccaatcac caactgttg  
13081 aagatgttgtt gtacacacac tggtacccagg caggcaatta ctgtacaccac agaaggctaa  
13141 atggaccaag agcccttgg tgggtgcata ttgtgttgtt attgtatgc ccacatgtac  
13201 catccaatc ctaaagggtt ctgtacttg aaaggtaatc acgtccaaat acccttaccc  
13261 tlgcataatg accgttggg ttttacactt aaaaacacag ctgtfaccgt ctggggaaatg  
13321 tggaaagggtt atggctgtt tggtgaccaa cttccggcaca ctttgcgtca gtcgtcgat  
13381 gcatcaacgt ttllaaacccg gtttgcgttgc taatgtgcgc cggcttaca cggcgttgc  
13441 caggcactag tactgtatgc gtcacccggg ctttgtatc ttacaacgaa aaaggctgt  
13501 gtttgcataa gtttgcataaa actaatgtct gtgcgttcca ggagaaggat gggaaaggca  
13561 atttatttgc ttcttactt gtatgttgc ggcataactt gtcactatc caacatgttgc  
13621 agactttaa taacttggtta aaaaatgttc cagcgttgc ttttttttttttttttttttttttt  
13681 tttagtgcata tgggtgcacatc ttacacgtca ggcgttactt aataatcaca  
13741 tggctgattt agtctatgtt ctatgttccat ttgtatggggg taatgttgtt acatattaa  
13801 aaatactcg tccatataatc tggatgtatgc atgtttttt caataaagaag gattgttatg  
13861 acttcgttgc gaaatccgtac atcttacccgc tatatgtctaa cttaggttgc cgtgttgc  
13921 aatcattttt aaaaatgttgc caatttgcgttgc atgtatgc ttttttttttttttttttttt  
13981 tactgtatc agataatcg gatcttgc gggaaatggta cgtttccgtt gatttttttttttttt  
14041 aagtatgcacc aggttgcggg gtttccatgtt tggttttttccatgttccatgttcc  
14101 tccctactt gactatggca tgggtgttgc agtccatgtt ggtatgttgc ttttttttttt  
14161 cacttataatggggatggt ctgaaatatg atttttacgggaa agagagactt ttttttttttt  
14221 accgtttttttaatgttgc gggccatcatc accatcccaatggtttttttttttttttttttt  
14281 atagggttatc ttcttacttgc gcaaaatttttaatgttgc ttttttttttttttttttttt  
14341 caagtttttgc accactatgtt aaaaaatatggtttgc ttttttttttttttttttttttt  
14401 ctggalaccat ttt  
14461 cccgttccatgttcaaggaa cttt  
14521 ctggcaatttt attgtatgc aaaaatgttgc catgttttgc agttagtgc ttttttttttt  
14581 atgttgc ttt  
14641 ttt  
14701 aggatggcaat cccgttccatgttgc ttttttttttttttttttttttttttttttttt  
14761 gtatgtatgc acaacttccat ttttttttttttttttttttttttttttttttttttttt  
14821 atggggctt ttt  
14881 tcccttt  
14941 aagatgttgc ttt  
15001 ttt  
15061 gtactatgc aaaaatgttgc ttttttttttttttttttttttttttttttttttttt  
15121 gggcttccatgttgc ttt  
15181 ctgttt  
15241 gagccatgttgc ttt  
15301 ctgttt  
15361 gtatgtatgc aaaaatgttgc ttttttttttttttttttttttttttttttttt  
15421 atgttgc ttt  
15481 ttt  
15541 aacacccgggtt ctatgttgc ttttttttttttttttttttttttttttttt  
15601 atgttt  
15661 ttt  
15721 ctgttt  
15781 acctt  
15841 atgttt  
15901 ttt  
15961 ttt  
16021 att  
16081 cccgttccatgttgc ttttttttttttttttttttttttttttt  
16141 ttt  
16201 ctgttttttttttttttttttttttttttttttttttttttt

FIG. 3F

**FIG. 3G**


19621 ttccatcat taataatgtt gttacacaa aggttagatgg tattgtatgt gagatcttg  
19681 aaaataagac aacacttcgtt cttatgttgc ctttgcataag cgtaacatta  
19741 aaccagtgcg agagaltaag atactcaata attgggtgt tgatatcgct gctaatactg  
19801 taatctggaa ctacaaaaga gaagccccag cacatgtatc tacaatagg1 gtctgcacaa  
19861 tgactgacat tgccaaagaaa cctactgaga gtgctgttc ttcaacttact1 gtcitgttgg  
19921 atggtagagt ggaaggacag gttagaccctt ttgaaaaacgc ccgtaatgg1 gtttaataaa  
19981 cagaagggtt cgtcaaaagg1 cttaacaccctt caaaggggacc agcacaagg1 agcgtcaatgg  
20041 gatgcacatt aattggagaa tcgtaaaaaaaaa cagatgtt1 ctatcttaag aaatggagac  
20101 gcattatcca acatgtgc1 gaaaaccttact1 cttactcagag cagagactta gaggatttt  
20161 agcccagatc acaaattggaa actgactt1 tcgagctcg1 tatggatgaa ttccatcacagc  
20221 galataagctt cggggctat gccttcgaac acatgtt1 lggagatttc agtcatggac  
20281 aacttggcg1 ttcttcaat1 atgataggct tagccaaagg1 ctccacaagg1 tcaccactt  
20341 aatttagagga ttatccat1 atggacagca cttgtaaaaaa ttacttcata acagatcgcc  
20401 aaacagggtt1 atcaaaatgtt gtgtgtctg1 tgatgtatctt ttacttgc1 gacttgtcg  
20461 agataataaa gtccacaagg1 ttgtcag1 tttcaaaagg1 ggtcaagg1 tttcaattgtact  
20521 atgtcgaaat1 ttcatcatt1 ctttgggt1 aggtatggca1 tttgtggaa1 ttcttacccaa  
20581 aactacaagg1 atgtcgagg1 tggcaaccagg1 gtgtgtcg1 gcttaactt1 tacaatggatgc  
20641 aaagaatgtt ttgtggaa1 tttgtggcc1 agaaatltt1 tgaaaaatgtt1 gtatataccaa  
20701 aaggaataat1 gtatgtt1 gcaaaagg1 ctcaactt1 tcaatctta aatacactt  
20761 tttagtgc1 acccttacac1 attagagg1 ttcaactt1 gg1 tttgtcg1 gataaaggag  
20821 ttgcaccagg1 tacagctgt1 cttagacaa1 ggttgc1 aac1 tggccacta1 ctgtcgat  
20881 cagatctt1 tgacttcgtc1 tccgacgc1 atttactt1 aattggagac1 tttgtcaacag  
20941 tacatccggc1 taataatgg1 gaccc1 tttttttttt1 ttatgtatgtt1 gtatggcc1 aggacccaaac  
21001 atgtgacaaa1 agagaatgac1 tctaaagg1 ggtttt1 cttatgtt1 ggtttt1  
21061 agcaaaaactt1 agccctgggt1 ggttctat1 ctgtttttt1 aacagagat1 tcttggat1  
21121 ctgac1 tttt1 caagttat1 ggcattt1 catgggg1 agctttt1 gttttttt1  
21181 atgcacat1 atccgg1 aac1 tttttttt1 ggg1 gttttt1 actt1 tttttt1  
21241 aaattgtat1 ctatccat1 catgtt1 acat1 tttt1 ctg1 ggg1 aac1 caca1  
21301 agtgc1 ctatccat1 ttttgc1 atttttt1 gttttttt1 ctatccat1  
21361 ctgtatgt1 ttttgg1 aatcaat1 atgtatgt1 ttatctt1 ctgggggggg  
21421 gttaggtttt1 cttttttt1 aac1 aac1 aac1 aac1 aac1 aac1 aac1  
21481 actt1 aac1  
21541 accgg1 gtc1 cactttt1 gatgtt1 caag1 ctcc1 aat1 cactt1 cat1 ct1  
21601 tgagggggg1 ttactat1 ctg1 gttttt1 ttatgtat1 cactt1 tttt1  
21661 attttttt1 tcc1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
21721 gcaacc1 tttt1 catac1 tttt1 aagg1 gttt1 ttat1 tttt1  
21781 ttgtcc1 tttt1 ttgggg1 tttt1 tttt1 tttt1 tttt1 tttt1  
21841 ttaac1 attt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
21901 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
21961 ttaat1 gtc1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22021 gtaat1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22081 ataagg1 gttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22141 aac1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22201 ctttt1 cacc1 tg1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22261 taaagg1 ccaac1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22321 atgt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22381 aagg1 aattt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22441 ctaat1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22501 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22561 actt1 aac1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22621 ttgtcc1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22681 tagcc1 ccc1 aac1 aac1 aac1 aac1 aac1 aac1 aac1 aac1  
22741 tgggg1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22801 attttttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22861 atgt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1  
22921 cattaaat1 gttt1 tttt1 tttt1 tttt1 tttt1 tttt1 tttt1

FIG. 3H


FIG. 3I

**FIG. 3J**

29701 atttaatag cttcttagga gaatgacaaa aaaaaaaaaaa aaaaaaaaaaa a  
//



**Fig. 5. The Subgenomic HCV Replicon Used to Test  
The Efficacy of siRNA in Human Liver Cells**




Neo: neomycin phosphotransferase gene

Luc: fruit fly luciferase


EMCV: internal ribosome entry site taken from EMCV

NS3, NS4A, NS4B, NS5A, and NS5B: HCV nonstructural proteins


**Fig. 6. The Effect of siRNA<sub>5</sub> on HCV Replication  
In Huh 5-2 Cells**




**Fig. 7. Sequence Specificity Required for Mediating RNA Interference in Huh7 Cells**




**Fig. 8. The Effect of siRNA5 of Cell Viability Measured by Cellular ATPase Activity**



**Fig. 9. The Effect of siRNAs on HCV Replication in Huh-7 Cells Measured by HCV RNA Assay**



**Fig. 10**




FIG. 11




**Fig. 12**

Fig. 13



**Fig. 14**




FIG. 15




Fig. 16

## MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE

This application is a divisional of U.S. application Ser. No. 10/626,879 filed Jul. 25, 2003, which claims priority to U.S. Provisional Application Nos. 60/470,230 filed May 14, 2003, 60/461,838 filed Apr. 11, 2003 and 60/398,605 filed Jul. 26, 2002, the contents of which are incorporated herein by reference in their entirety.

### SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Sep. 17, 2013, is named PAT051713-US-DIV02\_SL.txt and is 49,748 bytes in size.

### BACKGROUND OF THE INVENTION

The present invention relates to the field of nucleic acid detection and to the phenomenon of RNA silencing, or RNA interference (RNAi). RNA silencing constitutes a phenomenon wherein non-coding RNA molecules mediate specific gene suppression in an organism. In nature, the phenomenon protects an organism's genome from foreign, invading nucleic acids such as transposons, trangenes and viral genes.

The introduction of double-stranded RNA (dsRNA) into a cell triggers RNA silencing, which then degrades endogenous mRNA corresponding to the dsRNA. RNA silencing pathways involve a conversion of dsRNA into short interfering RNAs (siRNAs) that direct ribonucleases to homologous mRNA targets (Baulcombe et al., 2001). An enzyme called Dicer processes the dsRNA into siRNAs, which are 20-25 nucleotides long. The siRNAs then assemble into endoribonuclease-containing complexes known as RNA-induced silencing complexes (RISCs). Subsequently, the siRNAs guide the RISCs to complementary RNA molecules, where the RISCs cleave and destroy the target mRNA. Small amounts of dsRNA can silence a large amount of target mRNA due to an amplification component of RNA silencing (Fire et al., *Nature*, 391:806-811 (1998)).

The first evidence that dsRNA produces efficient gene silencing through RNAi came from studies on the nematode *Caenorhabditis elegans* (Fire et al., *Nature*, 391:806-811 (1998) and U.S. Pat. No. 6,506,559). Later studies in the fruit fly *Drosophila melanogaster* demonstrated that RNAi is a multi-step mechanism (Elbashir et al., *Genes Dev.*, 15(2): 188-200 (2001)).

Although dsRNA can mediate gene-specific interference in mammalian cells (Wianny, F. and Zernicka-Goetz, M., *Nature Cell Biol.* 2:70-75 (2000) Svoboda, P. et al., *Development* 17:4147-4156 (2000)), the use of RNAi in mammalian somatic cells is often limited by a triggering of dsRNA-dependent protein kinase (PKR), which inactivates the translation factor eIF2a, causes a generalized suppression of protein synthesis and often times causes apoptosis (Gil, J. and Esteban, M., *Apoptosis* 5:107-114 (2000)).

Recently, siRNA of approximately 21 or 22 base pairs in length, corresponding to targeted RNA or DNA sequences, were shown to disrupt the expression of the targeted sequences in mammalian cells (Elbashir, S. M., et al., *Nature* 411: 494-498 (2001)). However, it is not clear that all RNA or DNA sequences of a mammalian cell's genome are susceptible to siRNA. It is also uncertain that every mammalian cell type possesses the necessary machinery for effectuating gene-specific suppression using siRNA. Further, siRNA is of

limited use for at least two reasons: (a) the transient nature of the suppression effect seen in cells where the siRNA has been administered, and (b) the necessity for chemical synthesis of siRNAs before their use (Tuschl, T., *Nature Biotech.*, 20: 446-448 (2002)). Also, since siRNAs are unstable in vivo, their long-term effectiveness is limited.

An invention that addresses these challenges will improve the utility of RNAi for treating human disease at the level of nucleic acid activity. In particular, such an invention will make RNAi a more practical therapy for viral infections, such as infections with HCV. Current therapies for such viral infections are very limited, and tend to have poor response rates.

### SUMMARY OF THE INVENTION

The present invention provides double-stranded RNA (dsRNA) molecules that mediate RNA interference in target cells. In particular, it provides small interfering RNAs (siRNAs) that inhibit viral replication in infected cells. Preferred dsRNA molecules of the invention correspond to hepatitis C virus (HCV) nucleic acids, and inhibit replication of HCV in hepatic cells.

In another aspect, the invention provides modified dsRNA, including siRNA, molecules that are protected against nuclease degradation, but are able to inhibit viral replication in mammalian cells.

The invention also provides methods of inhibiting viral replication in infected cells by administering dsRNA or siRNA molecules. Modified dsRNA and siRNA molecules are particularly useful in these methods, as they are nuclease resistant, yet retain the biological activity of being able to inhibit viral replication by targeting an RNA sequence in a virus.

The invention further provides a method of making modified siRNAs that target a viral RNA or DNA sequence. The method comprises preparing a dsRNA fragment that contains at least one modified ribonucleotide in at least one strand, and cleaving the dsRNA fragment with Dicer enzyme, resulting in more than one modified siRNA.

Other objects, features and advantages of the invention will become apparent from the following detailed description. The description and specific examples indicate preferred embodiments, but should not be considered limiting, as various modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description. Further, the examples demonstrate the principle of the invention, but cannot be expected to specifically illustrate all useful applications.

### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the sequence and secondary structure of the 5' UTR from the HCV genome (SEQ ID NO: 9). It also provides specific sequences of siRNAs for inducing RNAi toward HCV in hepatic cells (SEQ ID NOS: 1-4, 68-69, and 7-8, respectively in order of appearance).

FIG. 2 provides sequences for several HCV-specific siRNAs that are useful for inducing RNAi toward HCV in hepatic cells. Each HCV-specific siRNA is identified by the designation provided in the first column. The sequences shown on the left are SEQ ID NOS: 10-28 and the sequences shown on the right are SEQ ID NOS: 29-66, respectively in order of appearance.

FIG. 3A shows the nucleotide sequence (1-2820) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3B shows the nucleotide sequence (2821-6180) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3C shows the nucleotide sequence (9181-9540) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3D shows the nucleotide sequence (9541-12900) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3E shows the nucleotide sequence (12901-16260) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3F shows the nucleotide sequence (16261-19620) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3G shows the nucleotide sequence (19621-22980) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3H shows the nucleotide sequence (22981-26340) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3I shows the nucleotide sequence (26341-29700) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 3J shows the nucleotide sequence (29701-29751) of the SARS coronavirus (SEQ ID NO: 67).

FIG. 4 is a schematic representation of the open reading frames of the SARS coronavirus (bases 27263-27272 of SEQ ID NO: 67 are shown).

FIG. 5 depicts a subgenomic HCV replicon contained in the hepatoma cell line Huh 7, which was used to test the efficacy of siRNA in human liver cells.

FIG. 6 depicts the dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line), that were administered different concentrations of siRNAs5. Luciferase activity, which was measured at 1, 2 and 3 days post-transfection, fell with increasing doses of siRNA. The luciferase assay was performed using a Luciferase assay system available from Promega Corp. (Madison, Wis.), according to the manufacturer's instructions.

FIG. 7 depicts the sequence specificity of siRNAs5 for inducing HCV-directed RNAi in Huh-7 liver cells.

FIG. 8 demonstrates that siRNAs5 is not toxic to Huh-7 cells. ATPase levels were assayed using an ATPase assay kit available from Promega Corp. (Madison, Wis.), according to the manufacturer's instructions.

FIG. 9 depicts the effects of siRNAs5 on HCV replication in 21-5 cells (Huh-7 cells containing full-length HCV), as measured by RNA assay. RNA levels were assayed using a Taq-Man<sup>TM</sup> RNA kit (F. Hoffman La-Roche, Switzerland), according to the manufacturer's instructions. Values are normalized.

FIG. 10 demonstrates that siRNAs5 does not affect the viability of Huh 5-2 cells. Specifically, mRNA encoding GAPDH, an enzyme essential to glycolysis was measured in Huh 5-2 cells transfected with siRNAs5 or GAPDH-specific siRNA. The graph demonstrates that siRNAs5 did not affect RNA levels of GAPDH. GAPDH was measured using a Taq-Man<sup>TM</sup> RNA kit (F. Hoffman La-Roche, Switzerland), according to the manufacturer's instructions. Values are normalized.

FIG. 11 depicts a dose response of normalized luciferase activity in Huh 7 cells containing a subgenomic HCV replicon (5-2 line) that were administered different concentrations of 2'-fluoro-siRNA (2'-F-GL2), which targets the fruit fly luciferase gene. Luciferase activity, which was measured at 2 days post-transfection, fell with increasing doses of siRNA. The luciferase assay was performed using a Firefly Luciferase kit (Promega Corp., Madison, Wis.), according to the manufacturer's instructions.

FIG. 12 demonstrates an inhibition of luciferase activity in 5-2 cells using the siRNA Chol-GL2 in the absence of liposomes.

FIG. 13 depicts an autoradiograph of 5'-labeled siRNA duplexes separated by PAGE, and shows the stability of 2'-fluoro-modified siRNA (2'-F-GL2) incubated in human

serum for up to 10 days. The siRNA duplexes were subjected to incubation with human serum and analysis by 20% PAGE. The composition of the lanes is as follows: Lanes 1, 11 and 21: <sup>32</sup>P-end labeled siRNA alone; Lanes 2-10, 12-20 and 22-25: siRNA incubated with human serum. Lanes 2 & 12, 1 min; Lanes 3 & 13, 5 min; Lanes 4 & 14, 15 min; Lanes 5 & 15, 30 min; Lanes 6 & 16, 1 hr; Lanes 7 & 17, 2 hr; Lanes 8 & 18, 4 hr; Lanes 9 & 19, 8 hr; Lanes 10 & 20, 24 hr; Lanes 22, 24 hr; Lanes 23, 48 hr; Lanes 24, 120 hr; Lanes 25, 240 hr incubation, respectively.

FIG. 14 demonstrates the use of recombinant human dicer to convert fluorinated dsRNA into 2'F-siRNA. The composition of the lanes is as follows: Lane 1: size marker, λ/HindIII+φX174/HaeIII; Lane 2: ribo/ribo homoduplex RNA; Lane 3: ribo/2'-F heteroduplex RNA; Lane 4: 2'-F/ribo heteroduplex RNA; Lane 6: size marker, 10 bp DNA ladder; Lane 7: ribo/ribo homoduplex siRNA; Lane 8: ribo/2'-F heteroduplex siRNA; Lane 9: 2'-F/ribo heteroduplex siRNA; Lane 10: 2'-F/2'-F homoduplex siRNA.

FIG. 15 shows a dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line) to HCV-specific siRNAs. Luciferase activity fell with increasing doses of each siRNA.

FIG. 16 shows that cholesterol shows a dose response of normalized luciferase activity in Huh-7 cells containing the subgenomic HCV replicon (5-2 line) to cholesterol-modified GL2 siRNA.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides dsRNA molecules that are about 10 to about 30 nucleotides long, and that mediate RNA interference in target cells. Preferably, the inventive molecules are chemically modified to confer increased stability against nuclease degradation, but retain the ability to bind to target nucleic acids.

As used herein, "RNA interference" (RNAi) refers to sequence-specific or gene specific suppression of gene expression (protein synthesis) that is mediated by siRNA, without generalized suppression of protein synthesis. While the invention is not limited to a particular theory or mode of action, RNAi may involve degradation of messenger RNA (mRNA) by an RNA-induced silencing complex (RISC), preventing translation of the transcribed mRNA. Alternatively, it may involve methylation of genomic DNA, which shunts transcription of a gene. The suppression of gene expression caused by RNAi may be transient or it may be more stable, even permanent.

"Gene suppression", "targeted suppression", "sequence-specific suppression", "targeted RNAi" and "sequence-specific RNAi" are used interchangeably herein. Furthermore, sequence-specific suppression, as used herein, is determined by separately assaying levels of the protein targeted for suppression in cells containing the siRNA (experimental cells) and in cells not containing the identical siRNA (control cells), then comparing the two values. Experimental and control cells should be derived from the same source and same animal. Also, control and experimental cells used in determining the level or quantity of gene suppression should be assayed under similar, if not identical, conditions.

RNA is a polymer of ribonucleotides, each containing the sugar ribose in association with a phosphate group and a nitrogenous base (typically, adenine, guanine, cytosine, or uracil). Like its cousin, DNA, RNA can form complementary hydrogen bonds. Therefore, RNA may be double-stranded (dsRNA), single-stranded (ssRNA) or double-stranded with a single-stranded overhang. Common types of RNA include

messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), micro RNA (miRNA) and small hairpin RNA (shRNA), each of which plays specific role in biological cells. As used herein, the term "RNA" includes all of these.

"Small interfering RNA" (siRNA) refers to double-stranded RNA molecules from about 10 to about 30 nucleotides long that are named for their ability to specifically interfere with protein expression. Preferably, siRNA molecules are 12-28 nucleotides long, more preferably 15-25 nucleotides long, still more preferably 19-23 nucleotides long and most preferably 21-23 nucleotides long. Therefore, preferred siRNA molecules are 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28 or 29 nucleotides in length.

The length of one strand designates the length of an siRNA molecule. For instance, an siRNA that is described as 21 ribonucleotides long (a 21-mer) could comprise two opposite strands of RNA that anneal together for 19 contiguous base pairings. The two remaining ribonucleotides on each strand would form an "overhang." When an siRNA contains two strands of different lengths, the longer of the strands designates the length of the siRNA. For instance, a dsRNA containing one strand that is 21 nucleotides long and a second strand that is 20 nucleotides long, constitutes a 21-mer.

siRNAs that comprise an overhang are desirable. The overhang may be at the 5' or the 3' end of a strand. Preferably, it is at the 3' end of the RNA strand. The length of an overhang may vary, but preferably is about 1 to about 5 bases, and more preferably is about 2 nucleotides long. Preferably, the siRNA of the present invention will comprise a 3' overhang of about 2 to 4 bases. More preferably, the 3' overhang is 2 ribonucleotides long. Even more preferably, the 2 ribonucleotides comprising the 3' overhang are uridine (U).

siRNAs of the present invention are designed to interact with a target ribonucleotide sequence, meaning they complement a target sequence sufficiently to bind to the target sequence. Preferably the target ribonucleotide sequence derives from a disease producing agent or pathogen. More preferably, the target ribonucleotide sequence is in a virus genome of an RNA virus or a DNA virus. Even more preferably, the virus is selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus.

Hepatitis C virus (HCV) is a highly preferred virus target. FIG. 1 and FIG. 2 disclose the nucleic acid sequences for several HCV-specific siRNA molecules. Among those shown, siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, and siRNA5B4 have shown particularly good activity, and therefore are highly preferred. siRNAs at least 80%, 90%, or 95%, identical to these highly preferred siRNAs also constitute part of the invention.

Another preferred virus target is the coronavirus, which is associated with upper respiratory infections in humans and recently has been linked with SARS (severe acute respiratory syndrome). Coronavirus has the largest known RNA virus genome, 32 kilobases long, and its genome is composed of positively stranded RNA. (See FIG. 5) Each coronavirus mRNA has a 5'-end leader sequence of 60 to 80 nucleotides that is identical to the 5'-UTR of genomic RNA approximately 200 nucleotides long. (See FIG. 6) These sequences are highly conserved, and therefore, provide an excellent source of target sequences for which siRNAs. See *Fundamental Virology*, 3<sup>rd</sup> Ed., Chapter 18, p. 541-560 (Eds. Fields, Knipe and Howley), Lippincott-Raven (1995). In one embodiment, the entire leader sequence (nucleotides 1-72) is

targeted. In another embodiment, one or more sections of the leader sequence is targeted. In a preferred embodiment, nucleotides 64-72 (TAAACGAAC) of the leader sequence are targeted. siRNA targeted to the coronavirus may be modified or unmodified.

In one embodiment, the invention provides an siRNA molecule comprising a ribonucleotide sequence at least 80% identical to a ribonucleotide sequence from a target agent or virus. Preferably, the siRNA molecule is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to the ribonucleotide sequence of the target agent or virus. The target can be the entire viral genome, a primary transcript, an open reading frame, or any portion of these. Most preferably, an siRNA will be 100% identical to the nucleotide sequence of a target agent or virus. However, siRNA molecules with insertions, deletions or single point mutations relative to a target may also be effective. Tools to assist siRNA design are readily available to the public. For example, a computer-based siRNA design tool is available on the internet at [www.dharmacon.com](http://www.dharmacon.com).

By way of example, a polynucleotide having a nucleotide sequence at least 95% "identical" to a reference nucleotide sequence means that the polynucleotide's sequence may include up to five point mutations per 100 nucleotides of the reference nucleotide sequence, or 1 point mutation per 20 nucleotides. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among 25 nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97% 98%, 99% or 100% identical to the ribonucleotide sequence of a target agent or 30 virus can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, Madison, Wis.). Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482-489 (1981)) to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference ribonucleotide sequence and that gaps in homology of up to 5% of the total number of ribonucleotides in the reference sequence are allowed.

The present invention also includes siRNA molecules that have been chemically modified to confer increased stability against nuclease degradation, but retain the ability to bind to target nucleic acids that may be present in cells. In the case where a target RNA is virus-specific, the modified siRNAs 35 are able to bind to the virus specific RNAs or DNAs, thereby inactivating the virus.

A modified siRNA of the present invention comprises a modified ribonucleotide, and is resistant to enzymatic degradation, such as RNase degradation, yet retains the ability to 40 inhibit viral replication in a cell containing the specific viral target RNA or DNA sequences. The siRNA may be modified at any position of the molecule so long as the modified siRNA

binds to a target sequence and is resistant to enzymatic degradation. Modifications in the siRNA may be in the nucleotide base, i.e., the purine or the pyrimidine, the ribose or the phosphate. Preferably, the modification occurs at the 2' position of at least one ribose in an siRNA.

More specifically, the siRNA is modified in at least one pyrimidine, at least one purine or a combination thereof. However, generally all pyrimidines (cytosine or uracil), or all purines (adenosine or guanine) or a combination of all pyrimidines and all purines of the siRNA are modified. More preferably, the pyrimidines are modified, and these pyrimidines are cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. Ribonucleotides on either one or both strands of the siRNA may be modified.

Ribonucleotides containing pyrimidine bases found in RNA (cytidine and uridine) can be chemically modified by adding any molecule that inhibits RNA degradation or breakdown of the base, the ribose or the phosphates. As previously noted, the 2' position of ribose is a preferred site for modification. 2' modified siRNAs have a longer serum half-life and are resistant to degradation, relative to unmodified siRNAs or single-stranded RNAs, such as antisense or ribozyme. 2'-modified pyrimidine ribonucleotides can be formed by a number of different methods known in the art.

A preferable chemical modification is the addition of a molecule from the halide chemical group to a ribonucleotide of siRNA. Within the halides, fluorine is a preferred molecule. Besides fluoro-, other chemical moieties such as methyl-, methoxyethyl- and propyl-may be added as modifications. The most preferred modification, though, is fluoro-modification, such as a T-fluoro-modification or a 2',2'-fluoro-modification.

Thus, in a preferred embodiment of the invention, siRNA is modified by the addition of a fluorine molecule to the 2' carbon of a pyrimidine ribonucleotide. The siRNA may be fluorinated completely or partially. For example, only the cytosine ribonucleotides may be fluorinated. Alternatively, only the uracil ribonucleotides may be fluorinated. In a preferred embodiment, both uracil and cytosine are fluorinated. Only one strand, either sense or antisense, of siRNA may be fluorinated. Even partial 2' fluorination of siRNA gives protection against nucleolytic degradation. Importantly, 2' fluorinated siRNA is not toxic to cells, an unexpected result given that fluorine chemistry usually is toxic to living organisms.

In addition, modified siRNAs of the present invention may contain chemical modifications that inhibit viral RNA polymerases. For example, siRNAs may comprise one or more nucleosides that inhibit viral RNA-dependent RNA polymerases. Examples of such nucleosides and other chemical modifications exist in WO 02/057425, WO 02/057287, WO 02/18404, WO 02/100415, WO 02/32920, WO 01/90121, U.S. Pat. No. 6,063,628 and US published application No. 2002/0019363.

siRNA can be prepared in a number of ways, such as by chemical synthesis, T7 polymerase transcription, or by treating long double stranded RNA (dsRNA) prepared by one of the two previous methods with Dicer enzyme. Dicer enzyme creates mixed populations of dsRNA from about 21 to about 23 base pairs in length from dsRNA that is about 500 base pairs to about 1000 base pairs in size. Unexpectedly, Dicer can effectively cleave modified strands of dsRNA, such as 2' fluoro-modified dsRNA. Before development of this method, it was previously thought that Dicer would not be able to cleave modified siRNA. The Dicer method of preparing siRNAs can be performed using a Dicer siRNA Generation Kit available from Gene Therapy Systems (San Diego, Calif.).

The invention particularly includes a method of making a modified siRNA that targets a nucleic acid sequence in a virus, comprising (a) preparing a modified-double stranded RNA (dsRNA) fragment containing at least one modified ribonucleotide in at least one strand, and (b) cleaving the modified-dsRNA fragments with recombinant human Dicer, resulting in more than one modified siRNA. The method may further comprise (c) isolating the modified siRNAs.

In the methods for making siRNA, a dsRNA fragment can be prepared by chemical synthesis or in vitro translation. In one embodiment, the modified siRNA is a 2' modified siRNA in which the modification is at the 2' position of at least one ribonucleotide of said siRNA. The modification is selected from the group consisting of fluoro-, methyl-, methoxyethyl and propyl-modification. Preferably the fluoro-modification is a 2'-fluoro-modification or a 2',2'-fluoro-modification. The pyrimidines, the purines or a combination thereof of the siRNA are modified. More preferably, the pyrimidines are modified, such as cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. One or both strands of the siRNA may contain one or more modified ribonucleotide.

The invention further provides a method of inactivating a target agent or virus in a patient by administering to the patient a dsRNA in an effective amount to inactivate the targeted agent or virus. Preferably the dsRNA is modified as described above. RNA interference toward a targeted DNA segment in a cell can be achieved by administering a double-stranded RNA molecule to the cells, wherein the ribonucleotide sequence of the double-stranded RNA molecule corresponds to the ribonucleotide sequence of the targeted DNA segment. Preferably, the dsRNA used to induce targeted RNAi is siRNA.

As used herein "targeted DNA segment" is used to mean a DNA sequence encoding, in whole or in part, an mRNA for a targeted protein, including introns or exons, where suppression is desired. DNA segment can also mean a DNA sequence that normally regulates expression of the targeted protein, including but not limited to the promoter of the targeted protein. Furthermore, the DNA segment may or may not be a part of the cell's genome or it may be extrachromosomal, such as plasmid DNA.

The present invention is particularly directed to a method of inactivating a virus in a patient by administering to the patient an siRNA, preferably a modified siRNA, in an effective amount to inactivate the virus. The siRNA is preferably about 10 to about 30 ribonucleotides in length, more preferably 12-28 ribonucleotides, more preferably 15-25 ribonucleotides, even more preferably 19-23 ribonucleotides and most preferably 21-23 ribonucleotides.

Also, the method of inactivating a virus preferably utilizes an siRNA that is modified at the 2' position of at least one ribonucleotide of said siRNA. The siRNA may be modified with chemical groups selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-. Fluoro-modification is most preferred, and either a 2'-fluoro-modification or a 2',2'-fluoro-modification is useful in the method. The modification may be at a pyrimidine, a purine or a combination thereof of the siRNA. More preferably the pyrimidines are modified, such as cytosine, a derivative of cytosine, uracil, a derivative of uracil or a combination thereof. In one embodiment, one strand of the siRNA contains at least one modified ribonucleotide, while in another embodiment, both strands of the siRNA contain at least one modified ribonucleotide.

siRNAs useful in treatment methods may also be modified by the attachment of at least one, but preferably more than one, receptor-binding ligand(s) to the siRNA. Such ligands

are useful to direct delivery of siRNA to a target virus in a body system, organ, tissue or cells of a patient, such as the liver, gastrointestinal tract, respiratory tract, the cervix or the skin.

In preferred embodiments, receptor-binding ligands are attached to either a 5'-end or a 3'-end of an siRNA molecule. Receptor-binding ligands may be attached to one or more siRNA ends, including any combination of 5'- and 3'-ends. Thus, when receptor binding ligands are attached only to the ends of an siRNA molecule, anywhere between 1 and 4 such ligands may be attached.

The selection of an appropriate ligand for targeting siRNAs to viruses in particular body systems, organs, tissues or cells is considered to be within the ordinary skill of the art. For example, to target an siRNA to hepatocytes, cholesterol may be attached at one or more ends, including any combination of 5'- and 3'-ends, of an siRNA molecule. The resultant cholesterol-siRNA is delivered to hepatocytes in the liver, thereby providing a means to deliver siRNAs to this targeted location. Other ligands useful for targeting siRNAs to the liver include HBV surface antigen and low-density lipoprotein (LDL).

As another example, siRNA molecules that target Human Immunodeficiency virus type 1 (HIV-1) can be delivered to T lymphocytes where the target nucleic acids are located (Song, E. et al., *J. of Virology*, 77(13): 7174-7181 (2003)). This delivery can be accomplished by attaching, at the 3'-end or 5'-end of siRNA molecules, HIV-1 surface antigen capable of binding to the CD4 surface protein located on T-cells (Kilby, M. et al., *New England J. of Medicine*, 348(22): 2228-38 (2003)).

Similarly, siRNA molecules that target Influenza A virus can be delivered to epithelial cells of the respiratory tract where the target nucleic acids are located (Ge, Q. et al., *Proc. Natl. Acad. of Sciences*, 100(5): 2718-2723 (2002)). This delivery can be accomplished by attaching, at the 3'-end or 5'-end of siRNA molecules, the Influenza virus surface antigen, which is capable of binding to the sialic acid residues located on the surface of the epithelial cells (Ohuchi, M., et al., *J. of Virology*, 76(24): 12405-12413 (2002); Glick, G. et al., *J. of Biol. Chem.*, 266 (35): 23660-23669 (1991)).

Also, siRNA molecules that target respiratory syncytial virus (RSV) can be delivered to epithelial cells of the respiratory tract where the target nucleic acids are located (Bitko, V. et al., *BMC Microbiology*, 1:34 (2001)). This delivery can be accomplished by attaching, at the 3'-end or 5'-end of siRNA molecules, RSV surface antigen (Malhotra, R. et al., *Microbes and Infection*, 5: 123-133 (2003)).

As still another example, siRNAs that target Human Papillomavirus (HPV) can be delivered to basal epithelial cells where the target nucleic acids are located (Hall, A. et al., *J. of Virology*, 77(10): 6066-6069 (2003)). This delivery can be accomplished by attaching, at the 3'-end or 5'-end of siRNA molecules, HPV surface antigen capable of binding to heparin sulfate proteoglycans located on the surface of basal epithelial cells (Bousarghin L. et al., *J. of Virology*, 77(6): 3846-3850 (2002)).

Further, siRNAs that target Poliovirus (PV) can be delivered to cells of the nervous system where the target nucleic acids are located (Gitlin, L. et al., *Nature*, 418: 430-434 (2002)). This delivery can be accomplished by attaching, at the 3'-end or 5'-end of siRNA molecules, PV surface antigen capable of binding to the CD155 receptor located on the surface of neurons (He, Y. et al., *Proc. Natl. Acad. of Sciences*, 97 (1): 79-84 (2000)).

As noted, the methods of treatment are intended to target disease-causing agents or pathogens, and more particularly viruses, which can be either RNA viruses or DNA viruses.

Preferred viruses are selected from the group consisting of hepatitis C virus (HCV), hepatitis A virus, hepatitis B virus, hepatitis D virus, hepatitis E virus, Ebola virus, influenza virus, rotavirus, reovirus, retrovirus, poliovirus, human papilloma virus (HPV), metapneumovirus and coronavirus. More preferably the target virus is hepatitis C virus or a coronavirus.

In one aspect, the method utilizes an siRNA prepared by (a) identifying a target ribonucleotide sequence in a virus genome for designing a small interfering RNA (siRNA) and (b) producing a siRNA that has been modified to contain at least one modified ribonucleotide. Preferably, the siRNA comprises a double-stranded RNA molecule with a first strand ribonucleotide sequence corresponding to a ribonucleotide sequence corresponding to a target ribonucleotide sequence in the virus, and a second strand comprising a ribonucleotide sequence complementary to the target ribonucleotide sequence. The first and second strands should be separate complementary strands that hybridize to each other to form a double-stranded RNA molecule. Moreover, one or both of the strands should comprise at least one modified ribonucleotide.

In preferred embodiments of the invention, the siRNA targets a ribonucleotide sequence in the hepatitis C virus genome. The target ribonucleotide sequence comprises a conserved ribonucleotide sequence necessary for HCV replication, and the conserved ribonucleotide sequence is selected from the group consisting of 5'-untranslated region (5'-UTR), 3'-untranslated region (3'-UTR), core, and NS3 helicase. Highly preferred siRNA molecules comprise a sequence at least 80% identical to those of siRNA5, siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, or siRNA5B4. The siRNAs may be unmodified, or modified as described above.

Methods of inhibiting the replication of HCV in cells positive for HCV should not be toxic to the cells, or cause apoptosis in the treated cells. Preferably, the inhibition of HCV replication is specifically tailored to affect only HCV replication in the cells, such that normal growth, division or metabolism is not affected. Cells in which HCV has been shown to replicate include, but are not limited to hepatic cells, B cell lymphocytes and T cell lymphocytes. Preferably, a method of inhibiting the replication of HCV is performed in hepatic cells.

According to the invention, "hepatic cells" can be from any animal source. Further, the hepatic cells may be in cell culture, or part of a tissue, or an organ, in part or in whole. The phrase hepatic cells is meant to include any cell constituting a normal, abnormal or diseased liver cell. Examples of hepatic cells include, but are not limited to, Kupffer cells, hepatocytes and cells comprising a hepatocellular carcinoma. "Hepatic cells" is not meant to include cells that make up discrete structures within the liver, such as endothelial cells lining blood vessels. A tissue or organ containing the hepatic cells may be within a subject or may be biopsied or removed from the animal. Additionally, the tissue may be "fresh" in that the tissue would be recently removed from a subject, without any preservation steps between the excision and the methods of the current invention. Prior to application of the methods of the current invention, the tissue may also have been preserved by such standard tissue preparation techniques including, but not limited to, freezing, quick freezing, paraffin embedding and tissue fixation. Furthermore, the tissue may also be a xenograft or a syngraft on or in another host animal. As used herein, the terms animal and subject are used interchangeably.

According to the invention, "hepatitis C virus," or "HCV," takes its ordinary meaning in the art as of the date of inven-

## 11

tion. The hepatitis C virus is an RNA virus of the Flaviviridae family. For example as used herein, HCV includes, but is not limited to genotypes 1-11 (using the most common genotyping system), with these genotypes being broken down into sub-types, some of which include but are not limited to 1a, 1b, 1c, 2a, 2b, 2c, 3a, 3b, 4a, 4b, 4c, 4d, 4e, 5a, 6a, 7a, 7b, 8a, 8b, 9a, 10a and 11a. Further, isolates from individuals consist of closely related yet heterogeneous populations of viral genomes, sometimes referred to as quasispecies.

Pestivirus is yet another target of the present invention. As used herein, "pestivirus" takes its ordinary meaning in the art as of the date of invention. The pestivirus belongs to the family Flaviviridae. Pestivirus is widespread throughout the Australian cattle population. It is believed that about 70% of herds are actively infected with pestivirus. Infection of susceptible animals can cause a variety of diseases—some not apparent until well after the initial spread of the virus into a herd. Pestivirus is a genus of viruses that includes hog cholera virus, bovine viral diarrhea virus (BVDV) and border disease virus (BDV) or hairy-shaker disease virus.

siRNA may be administered to a patient by intravenous injection, subcutaneous injection, oral delivery, liposome delivery or intranasal delivery. The siRNA may then accumulate in a target body system, organ, tissue or cell type of the patient.

The present invention also provides a method of inhibiting the replication of a virus in mammalian cells, comprising transfecting cells harboring the virus with a vector that directs the expression of virus-specific siRNA. In one embodiment, the invention provides a method of inhibiting the replication of hepatitis C virus (HCV) in cells positive for HCV, comprising transfecting HCV-positive cells with a vector that directs the expression of an HCV-specific siRNA. The cells may be evaluated to determine if a marker in the cells has been inhibited by the siRNA.

Thus, the invention also provides vectors and host cells comprising a nucleic acid segment encoding the described siRNAs.

Vectors of the present invention may be employed for producing siRNAs by recombinant techniques. Thus, for example, a DNA segment encoding an siRNA may be included in any one of a variety of expression vectors for expressing any DNA sequence. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in a desired host.

The appropriate DNA segment may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA segment in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct siRNA synthesis. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous Sarcoma Virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter. Preferably the promoters of the present invention are from the type III class of RNA polymerase III promoters. More preferably, the promoters are selected from the group consisting of the U6 and

## 12

H1 promoters. The U6 and H1 promoters are both members of the type III class of RNA polymerase III promoters. The promoters of the present invention may also be inducible, in that expression may be turned "on" or "off." For example, a tetracycline-regulatable system employing the U6 promoter may be used to control the production of siRNA. The expression vector may or may not contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or tetracycline or ampicillin resistance.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α-factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

In one embodiment, the invention provides a vector, wherein the DNA segment encoding the sense strand of the RNA polynucleotide is operably linked to a first promoter and where the DNA segment encoding the antisense (opposite) strand of the RNA polynucleotide molecule is operably linked to a second promoter. In other words, each strand of the RNA polynucleotide is independently expressed. Furthermore, the promoter driving expression of each strand can be identical or each one may be different from the other promoter.

In another embodiment, the vector of the current invention may comprise opposing promoters. For example, the vector may comprise two U6 promoters on either side of the DNA segment encoding the sense strand of the RNA polynucleotide and placed in opposing orientations, with or without a transcription terminator placed between the two opposing promoters. The U6 opposing promoter construct is similar to the T7 opposing promoter construct as described in Wang, Z. et al., J. Biol. Chem. 275: 40174-40179 (2000). See Miyagishi, M. and Taira, K., Nature Biotech. 20: 497-500 (2002).

In another embodiment, the DNA segments encoding both strands of the RNA polynucleotide are under the control of a single promoter. In one embodiment, the DNA segments encoding each strand are arranged on the vector with a "loop" region interspersed between the two DNA segments, where transcription of the DNA segments and loop region creates one RNA transcript. The single transcript will, in turn, anneal to itself creating a "hairpin" RNA structure capable of inducing RNAi. The "loop" of the hairpin structure is preferably from about 4 to about 6 nucleotides in length. More preferably, the loop is 4 nucleotides in length.

The vector containing the appropriate DNA sequence as described herein, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the siRNA. Appropriate

cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y. (1989), the disclosure of which is hereby incorporated by reference.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, cloning vectors or expression vectors. The vectors may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells may be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. A host cell may be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell may be a prokaryotic cell, such as a bacterial cell. Preferably, host cells are mammalian cells. More preferably, host cells are hepatic cells. Introduction of a construct into host cells can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., et al., Basic Methods in Molecular Biology (1986)).

The term patient, as used herein, refers to an animal, preferably a mammal. More preferably the patient can be a primate, including non-human and humans. The terms subject and patient are used interchangeably herein.

The treatments envisioned by the current invention can be used for subjects with a pre-existing viral infection, or for subjects pre-disposed to an infection. Additionally, the methods of the current invention can be used to correct or compensate for cellular or physiological abnormalities involved in conferring susceptibility to viral infections in patients, and/or to alleviate symptoms of a viral infections in patients, or as a preventative measure in patients.

The method of treating a patient having a viral infection involves administration of compositions to the subjects. As used herein, composition can mean a pure compound, agent or substance or a mixture of two or more compounds, agents or substances. As used herein, the term agent, substance or compound is intended to mean a protein, nucleic acid, carbohydrate, lipid, polymer or a small molecule, such as a drug.

In one embodiment of the current invention, the composition administered to the subject is a pharmaceutical composition. Further, the pharmaceutical composition can be administered orally, nasally, parenterally, intrasystemically, intraperitoneally, topically (as by drops or transdermal patch), buccally, or as an oral or nasal spray. Intranasal delivery of a virus that causes upper respiratory diseases, such as the coronavirus or the metapneumovirus, would be a particularly advantageous delivery mode. The term "parenteral," as used herein, refers to modes of administration that include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. The pharmaceutical compositions as contemplated by the current invention may also include a pharmaceutically acceptable carrier.

"Pharmaceutically acceptable carrier" includes, but is not limited to, a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type, such as liposomes.

A pharmaceutical composition of the present invention for parenteral injection can comprise pharmaceutically accept-

able sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the present invention can also contain adjuvants such as, but not limited to, preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorb acid, and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, to prolong the effect of the drugs, it is desirable to slow the absorption from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, can depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include, but are not limited to, capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compounds are mixed with at least one item pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form can also comprise buffering agents.

## 15

Solid compositions of a similar type can also be employed as fillers in soft and hard filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms can contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, can contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

Alternatively, the composition can be pressurized and contain a compressed gas, such as nitrogen or a liquefied gas propellant. The liquefied propellant medium and indeed the total composition is preferably such that the active ingredients do not dissolve therein to any substantial extent. The pressurized composition can also contain a surface active agent. The surface active agent can be a liquid or solid non-ionic surface active agent or can be a solid anionic surface active agent. It is preferred to use the solid anionic surface active agent in the form of a sodium salt.

The compositions of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the compounds of the invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are known in the art (see, for example, Prescott, Ed., *Meth. Cell Biol.* 14:33 et seq (1976)).

One of ordinary skill in the art will appreciate that effective amounts of the agents of the invention can be determined empirically and can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or pro-drug form. A "therapeutically effective" amount of the inventive compositions can be determined by prevention or ame-

## 16

lioration of adverse conditions or symptoms of diseases, injuries or disorders being treated. The agents can be administered to a subject, in need of treatment of viral infection, as pharmaceutical compositions in combination with one or more pharmaceutically acceptable excipients. It will be understood that, when administered to a human patient, the total daily usage of the agents or composition of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors: the type and degree of the cellular or physiological response to be achieved; activity of the specific agent or composition employed; the specific agents or composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the agent; the duration of the treatment; drugs used in combination or coincidental with the specific agent; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the agents at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosages until the desired effect is achieved.

Dosing also can be arranged in a patient specific manner to provide a predetermined concentration of the agents in the blood, as determined by techniques accepted and routine in the art. Thus patient dosaging can be adjusted to achieve regular on-going blood levels, as measured by HPLC, on the order of from 50 to 1000 ng/ml.

It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein can be made without departing from the scope of the invention or any embodiment thereof.

## EXAMPLES

The examples demonstrate that siRNA, including modified siRNA, can effectively inhibit viral replication in mammalian cells. Moreover, the examples show that the inventive siRNAs promote HCV RNA degradation in human liver cells and establish that hepatocytes possess the necessary functional components of modified siRNA-induced silencing. The examples also demonstrate that siRNA technology can be used as a therapy to inhibit HCV replication in host cells. The inventors, by submitting the following examples, do not intend to limit the scope of the claimed invention.

## Example 1

To test whether siRNA directed to the HCV genome confers intracellular immunity against this human pathogen, a recently developed HCV cell culture systems in human hepatoma cell line, Huh-7, was used. One of the cell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA (Bartenschlager, J. Virol, 2001). The subgenomic replicon carries firefly luciferase gene, allowing a reporter function assay as a measure of HCV RNA replication (FIG. 5). Owing to cell culture adaptive mutations introduced into the genome (Bart), these 5-2 cells replicate HCV RNA at levels of up to  $5 \times 10^4$  virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against different regions of the 5'-UTR of the HCV genome were made (FIG. 5). Briefly, 2 oligo double-stranded DNA molecules comprising the T7 promoter and the 5' UTR of HCV being oriented in either the sense direction or the anti-sense direction were generated. Each oligo DNA was then

17

transcribed in vitro to produce (+) and (-) RNA and then treated with DNAase I to remove the DNA template. The two RNA strands were allowed to anneal at 37° C. overnight, generating dsRNA. After treating the dsRNA with RNAase T1 to remove unreacted ssRNA species, the dsRNA was purified for transfection.

Several other siRNA duplexes were designed, including GL2 and GL3, that were directed against the fruit fly and sea pansy luciferase genes, respectively. Using standard transfection techniques, the siRNAs were transfected into the 5-2 cells and luciferase activity was measured to determine the effect of the siRNAs on HCV replication. Luciferase activity was measured 48 hours after transfection. In cells where siRNA5 was transfected, there was reduced luciferase activity of up to 85%, in a dose responsive manner (FIG. 6). The inhibition of luciferase activity was not seen in cells that were transfected with irrelevant siRNA (SIN). The sequence of SIN was taken from sindbis virus transcription promoter (FIG. 1).

#### Example 2

The sequence specificity of the siRNA5 response was further tested using additional siRNA duplexes, GL2 and GL3. FIG. 1 shows that GL2 and GL3 differ from each other by 3-nucleotides. Luciferase activity was reduced by 90% in cells transfected with siRNA5 or GL2, but no significant reduction was seen in cells transfected with GL3 (FIG. 7). The luciferase assay was performed using a Luciferase assay system available from Promega Corp. (Madison, Wis.), according to the manufacturer's instructions.

#### Example 3

Whether or not siRNA5 was toxic to transfected cells also was tested. Toxicity was measured using an ATPase activity assay. FIG. 8 shows that the siRNA5-induced reduction in HCV replication, as seen in FIG. 6, was not due to cellular toxicity which is attributed to non sequence-specific RNAi. ATPase levels were assayed using an ATPase assay kit from Promega (Madison, Wis.) according to the manufacturer's instructions.

#### Example 4

The full-length HCV replicon may possess the ability to adapt and suppress RNAi, thus replicating in spite of the presence of siRNA, as documented in Li, H, Science 296: 1319-1321 (2002). To determine the effects of siRNA5 on replication of full-length HCV RNA in Huh-7 cells, from the 21-5 cell line, harboring the selectable full-length HCV replicon, were treated with siRNA5. Levels of HCV RNA were measured by quantitative PCR using TaqMan™ (F. Hoffman La-Roche, Switzerland). The results as seen in FIG. 9 show that siRNA-directed silencing reduced steady-state viral RNA production, even in the setting of an adapted HCV mutant, where RNA replication was very high. Results from both subgenomic and full-length HCV replicons suggest that none of the HCV proteins can suppress RNA interference.

#### Example 5

Whether or not siRNA5 was toxic to transfected cells also was tested. Specifically, mRNA encoding GAPDH, an enzyme essential in glycolysis, was measured in Huh 5-2 cells transfected with siRNA5, or siRNA specific towards the GAPDH sequence. FIG. 10 demonstrates that siRNA5 did not

18

affect RNA levels of GAPDH. GAPDH was measured using a TaqMan™ RNA kit (F. Hoffman La-Roche, Switzerland) according to the manufacturer's instructions.

#### Example 6

To test the effectiveness of siRNA5 on inhibiting the ability of HCV to replicate in an infected liver, potions of HCV-infected human liver are xenografted onto transgenic severe combined immunodeficient (SCID) mice according to methods well known to the skilled artisan.

Briefly, once the HCV-infected liver has supplanted the mouse liver, liposome-encapsulated siRNA5, or control liposomes are administered by intravenous injection to the mice through the tail vein, or another accessible vein. The mice are dosed one time a day for 3-10 days.

At the end of the dosing regimen the mice are sacrificed and blood collected and the livers removed. The liver is divided into portions such that a portion is frozen using liquid nitrogen, a portion is fixed for paraffin embedding, and a portion is fixed for sectioning onto slides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™ RNA assay kit previously utilized herein to determine the levels of HCV RNA in the liver cells. Further, anti-HCV antibody titers can be measured in the collected blood samples, along with serum ALT levels.

#### Example 7

To test the effectiveness of siRNA5 on inhibiting the ability of HCV to infect a healthy liver, potions of normal human liver are xenografted onto transgenic severe combined immunodeficient (SCID) mice according to methods well known to the skilled artisan.

Briefly, once the healthy liver has supplanted the mouse liver, liposome-encapsulated siRNA5, or control liposomes are administered by intravenous injection to the mice through the tail vein, or another accessible vein. The mice are dosed one time a day for 3-10 days. After the pre-dosing regimen, active HCV is then injected intravenously, or via hepatic injection, into the mice.

At about 6, 12, 18, 24 hours, and periodically up to about 5 days after the mice are infected with HCV, the mice are sacrificed and blood collected and the livers removed. The liver is divided into portions such that a portion is frozen using liquid nitrogen, a portion is fixed for paraffin embedding, and a portion is fixed for sectioning onto slides.

Using the appropriate allotment, HCV RNA is quantified using the TaqMan™ RNA assay kit previously utilized herein to determine the levels of HCV RNA in the liver cells. Further, anti-HCV antibody titers can be measured in the collected blood samples, along with serum ALT levels.

#### Example 8

Modified siRNA can be prepared by chemical synthesis. In one embodiment, each C and U within a siRNA duplex, e.g. GL2, can be substituted with 2'-F-U and 2'F-C. To produce siRNA with 3'-end overhangs comprising 2'-F-U and 2'F-C, a universal support can be used. By selectively cleaving the oligo from the support, a practitioner can ensure that residues of the overhangs comprise modified nucleotides. Alternatively, the nucleotides comprising the 3'-end overhang can be unmodified dTdT.

2'-F RNA oligonucleotides can be synthesized on an Applied Biosystems 8909 or 8905 DNA/RNA synthesizer using the standard 1 μmol beta-cyanoethyl phosphoramidite

19

RNA chemistry protocol. The RNA phosphoramidite monomers and columns of Pac-A, 2'-F-Ac-C, iPr-Pac-G, 2'-F-U, and U-RNA CPG can be obtained from Glen Research (Sterling, Va.). (See catalog nos. 10-3000-05, 10-3415-02, 10-3021-05, 10-3430-02, and 20-3430-41E, respectively.) Glen Research's Sulfurizing Reagent (catalog no. 40-4036-10) can be used as an oxidant to obtain a single phosphorothioate backbone between the 3' CPG and a subsequent base. To attain the coupling, the oxidizing step of the standard RNA 1 μmol protocol can be replaced with the standard thioate 1 μmol protocol. Cholestryl-TEG phosphoramidite (Glen Research, catalog no. 10-1975-90) and cholestryl-TEG CPG (Glen Research, catalog no. 20-2975-41E) can be incorporated onto the 5' or 3' ends of one or more of the oligoribonucleotides. After synthesis, the 2'-F RNA's are cleaved and deprotected with 1:1 ammonium hydroxide/methylamine, and the silyl groups are removed with triethylamine trihydrofluoride using standard protocols. See e.g. [http://www.glenre.com/productfiles/technical/tb\\_rnadeprotection.pdf](http://www.glenre.com/productfiles/technical/tb_rnadeprotection.pdf). The oligoribonucleotides are then desalted on Sephadex G25 columns (Pharmacia NAP 25, catalog no. 17-08252-02) with sterilized water and purified using standard gel electrophoresis protocols. Modified siRNAs also can be obtained from commercial vendors such as Dharmacon (Lafayette, Colo.).

Alternatively, modified siRNA can be prepared by transcription using the DurascrIbe™ T7 Transcription Kit purchased from Epicentre Technologies (Madison, Wis.).

The modified siRNAs (dsRNAs) made by these methods contain phosphodiester linked oligonucleotides. Standard methods for making modified single-stranded RNAs, such as antisense molecules, are useful for making modified siRNAs, as modified single-stranded RNAs can be annealed together to form double stranded RNAs. Such standard methods include, but are not limited to, those described in Chiang et al., *J. Biol. Chem.* 266, 18162-18171 (1991); Baker et al., *J. Biol. Chem.* 272, 11994-12000 (1997); Kawasaki et al., *J. Med. Chem.* 36, 831-841 (1993); Monia et al., *J. Biol. Chem.* 268, 14514-14522 (1993).

#### Example 9

To test whether siRNA directed to the HCV genome confers intracellular immunity against this human pathogen, a recently developed HCV cell culture systems in human hepatoma cell line, Huh-7, was used. One of the cell lines, 5-2, harbors autonomously replicating subgenomic HCV RNA (Bartenschlager, J. Virol. 2001). The subgenomic replicon carries firefly luciferase gene, allowing a reporter function assay as a measure of HCV RNA replication. Owing to cell culture adaptive mutations introduced into the genome, 5-2 cells replicate HCV RNA at levels of up to  $5 \times 10^4$  virus particles/cell.

Using T7 transcription, several 21-bp siRNA duplexes against different regions of the 5'-UTR of the HCV genome were made. Briefly, two oligo double-stranded DNA molecules comprising the T7 promoter and the 5' UTR of HCV being oriented in either the sense direction or the antisense direction were generated. Each oligo DNA was then transcribed in vitro to produce (+) and (-) RNA and then treated with DNase I to remove the DNA template. The two RNA strands were allowed to anneal at 37°C overnight, generating dsRNA. After treating the dsRNA with RNAase T1 to remove the unreacted ssRNA species, the dsRNA was purified for transfection.

20

Two exemplary modified siRNAs are provided below (SEQ ID NOS 5-6 and 5-6, respectively, in order of appearance):

- |    |   |   |
|----|---|---|
| 5  | cho1-GL2  | Cho1 - CGUACGGAAUACUUCGAUU<br>UUGCAUGC GCC UUAUGAAGCU |
|    | GL2   | CGUACGGAAUACUUCGAUU<br>UUGCAUGC GCC UUAUGAAGCU        |
| 10 | Each C and U within siRNA GL2, directed against the fruit fly luciferase gene, was substituted with 2'-F-U and 2'-F-C. The modified siRNAs were transfected into the 5-2 cells using standard liposome transfection techniques. Specifically, the modified siRNAs were incubated for 4 hrs at 37°C. |   |
| 15 | in a 250 μl cell suspension containing 0.5 μl of Oligofectamine (Invitrogen, Carlsbad, Calif.), for 20 hrs in 375 μl serum containing culture medium, and for 24 hrs at 37°C in fresh medium without the liposome-siRNA complex. Luciferase activity was measured 48 hours after transfection       |   |
| 20 | to determine the effect of the modified siRNAs on HCV replication.  |   |

FIG. 11 shows that GL2 reduced the luciferase activity at increasing concentrations. Luciferase activity was reduced by 90% in cells transfected with 2'-F-GL2, but no significant reduction was seen in mocked transfected cells or with a control (2'-F-GFP=green fluorescent protein). The luciferase assay was carried out using a Luciferase assay system available from Promega Corp. (Madison, Wis.), according to the manufacturer's instructions.

The siRNA Chol-GL2 comprises a cholestryl group on one of the 5' ends. 5-2 cells were incubated with various concentrations of Chol-GL2 in the absence of liposomes. Cells were harvested 48 hours after incubation and assayed for luciferase activity. FIG. 12 shows that Chol-GL2 inhibited luciferase gene activity in a dose-dependent manner. InvA refers to chol-GL2 in inverted sequence.

#### Example 10

To test the stability of 2' chemically modified siRNA compared to unmodified siRNA (siRNA), the following experiment is performed. Four nanograms of siRNA are added to a 20 μL volume of 80% human serum from a healthy donor. This mixture is incubated at 37°C for various times ranging from 1 minute up to 10 days. The results are depicted in lanes 2-10 of FIG. 13. The same process is performed for 2' fluorine modified siRNA (2'-F siRNA) as well and the results are shown in lanes 12-20 and 22-25 of FIG. 3. When the incubation process is finished, the mixtures are placed on ice and then immediately separated by PAGE along with a  $^{32}$ P-siRNA control (See Lanes 1, 11 and 21 of FIG. 13). The data show that the 2'-modified siRNA is stable over a period of 10 days as compared to unmodified siRNA.

#### Example 11

To demonstrate the production of modified siRNA from long dsRNA, five micrograms of 1000 bp-long fluorinated dsRNAs (FIG. 14, panel (A)) were incubated overnight with 15 units of human Dicer at 37°C. The resulting diced-siRNAs were purified using a Sephadex G-25 column and electrophoresed on 20% PAGE (FIG. 14, panel (B)). FIG. 4 shows that recombinant human dicer effectively converts fluorinated-dsRNA into 2'F-siRNA.

#### Example 12

To further test whether siRNAs directed to the HCV genome confer intracellular immunity against this human pathogen, the assay described in Example 1 was employed to test siRNAC1, siRNAC2, siRNA5B1, siRNA5B2, and siRNA5B4, each of which is shown in FIG. 2. Each siRNA was tested at concentrations of 1 nM, 10 nM and 100 nM. As

**21**

shown in FIG. 15, each of the siRNAs significantly inhibited luciferase activity in a dose-dependent manner. SiRNAC2 exhibited particular effectiveness.

## Example 13

As a follow-up to the experiments reported in Example 9, assays were performed to demonstrate that the cholesterol

**22**

modification, and not the fluoro modification directed siRNA molecules to Huh-7 liver cells. Huh-7 cells were incubated with various concentrations of two kinds of Chol-GL2 siRNAs: one having a 2'-fluoro modification and the other lacking such a modification. The results, shown in FIG. 16 demonstrate that the delivery of cholesterol-modified siRNA molecules to liver cells is due to the cholesterol, and not other modifications.

## SEQUENCE LISTING

&lt;160&gt; NUMBER OF SEQ ID NOS: 69

<210> SEQ ID NO 1  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 1

guacugccug auagggugcu u

21

<210> SEQ ID NO 2  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 2

gcaccuccaua aggcaguacu u

21

<210> SEQ ID NO 3  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 3

cguacgcgga auacuucgau u

21

<210> SEQ ID NO 4  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 4

ucgaaguauu ccgcguacgu u

21

<210> SEQ ID NO 5  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 5

cguacgcgga auacuucgau u

21

<210> SEQ ID NO 6  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 6

ucgaaguauu ccgcguacgu u

21

<210> SEQ ID NO 7  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

-continued

&lt;400&gt; SEQUENCE: 7

aucucuacgg ugguccuaau u

21

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 21

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 8

uuaggaccac cguagagauu u

21

&lt;210&gt; SEQ ID NO 9

&lt;211&gt; LENGTH: 383

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 9

gcacgcccc ugaugggggc gacacuccac cauagaucac ucccccuguga ggaacuacug 60  
 ucuucacgca gaaagcgcu agcccauggcg uuaguauagag ugucgugcag ccuccaggac 120  
 cccccccuccc gggagagcca uaguggucug cggAACCGGG gaguacacccg gaaauugccag 180  
 gacgaccggg uccuuuuuug gaucaacccg cucaauggccu ggagauuugg gcgugccccc 240  
 gcaagacugc uagccgagua guguuggguc gcgaaaggcc uugugguacu gccugauagg 300  
 gugcuuggcga gugcccccggg aggucucgua gaccgugcac caugagcacg aauccuaac 360  
 cucaaagaaa aaccaaacgu aac 383

&lt;210&gt; SEQ ID NO 10

&lt;211&gt; LENGTH: 23

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 10

cccugugagg aacuacuguc uuc

23

&lt;210&gt; SEQ ID NO 11

&lt;211&gt; LENGTH: 23

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 11

uacugucuuc acgcagaaag cgu

23

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 23

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 12

cgagacugcu agccgaguag ugu

23

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 23

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 13

gaaucuaaa ccucaaagaa aaa

23

&lt;210&gt; SEQ ID NO 14

&lt;211&gt; LENGTH: 23

-continued

<212> TYPE: RNA  
 <213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 14

ggucagaucg ucgguggagu uua

23

<210> SEQ ID NO 15

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 15

gguaaggua ucgauaaccu cac

23

<210> SEQ ID NO 16

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 16

acggcugaa ouaugcaaca ggg

23

<210> SEQ ID NO 17

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 17

cggguugcuc cuuuucuauc uuc

23

<210> SEQ ID NO 18

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 18

gcucuuucaua cggauuccaa uac

23

<210> SEQ ID NO 19

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 19

cauacggauu ccaauacucu ccu

23

<210> SEQ ID NO 20

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 20

uuugacucaa cggucacuga gaa

23

<210> SEQ ID NO 21

<211> LENGTH: 23

<212> TYPE: RNA

<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 21

ccuucacgga ggcuaugacu aga

23

<210> SEQ ID NO 22

## US 9,139,833 B2

**27****28**

-continued

```

<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 22
auacgacuug gaguugauaa cau                                23

<210> SEQ ID NO 23
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 23
auuuccuggcu aggcaacauc auc                                23

<210> SEQ ID NO 24
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 24
uuguggcaag uaccucuuca acu                                23

<210> SEQ ID NO 25
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 25
auguggugcc uacuccuacu uuc                                23

<210> SEQ ID NO 26
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 26
cuuugguggc uc当地uuuag ccc                                23

<210> SEQ ID NO 27
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 27
gucacggcuu gcugugaaag guc                                23

<210> SEQ ID NO 28
<211> LENGTH: 23
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 28
agccgc当地uuga cugcagagag ugc                                23

<210> SEQ ID NO 29
<211> LENGTH: 21
<212> TYPE: RNA
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 29
cugugaggaa cuacugucuu c                                21

```

-continued

<210> SEQ ID NO 30	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 30	
agacaguagu uccucacagg g	21
<210> SEQ ID NO 31	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 31	
cugucuuucac gcagaaagcg u	21
<210> SEQ ID NO 32	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 32	
guuuucugcg ugaagacagu a	21
<210> SEQ ID NO 33	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 33	
agacugcuag ccgaguagug u	21
<210> SEQ ID NO 34	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 34	
acuacucggc uagcagucuc g	21
<210> SEQ ID NO 35	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 35	
auccuaaacc ucaaagaaaa a	21
<210> SEQ ID NO 36	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 36	
uuucuuuugag guuuaggauu c	21
<210> SEQ ID NO 37	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 37	
ucagauccgc gguggaguuu a	21

-continued

<210> SEQ ID NO 38  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 38

aacuccaccg acgaucugac c

21

<210> SEQ ID NO 39  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 39

uaagguauc gauaccuca c

21

<210> SEQ ID NO 40  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 40

gaggguaucg augaccuuac c

21

<210> SEQ ID NO 41  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 41

ggcgugaacu augcaacagg g

21

<210> SEQ ID NO 42  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 42

cuguugcaua guucacgccc u

21

<210> SEQ ID NO 43  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 43

gguugcuccu uuucuaucuu c

21

<210> SEQ ID NO 44  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 44

agauagaaaa ggagcaaccg g

21

<210> SEQ ID NO 45  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 45

ucuucauacg gauuccaaaua c

21

-continued

<210> SEQ ID NO 46  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 46

auuggaaucc guaugaagag c

21

<210> SEQ ID NO 47  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 47

uacggauucc aaucacucucc u

21

<210> SEQ ID NO 48  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 48

gagaguauug gaauccguau g

21

<210> SEQ ID NO 49  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 49

ugacucaacg gucacugaga a

21

<210> SEQ ID NO 50  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 50

cucagugacc guugagucaa a

21

<210> SEQ ID NO 51  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 51

uucacggagg cuaugacuag a

21

<210> SEQ ID NO 52  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 52

uagucauagc cuccgugaag g

21

<210> SEQ ID NO 53  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

<400> SEQUENCE: 53

-continued

acgacuuggga guugauaaca u

21

<210> SEQ ID NO 54  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 54

guuaucacu ccaagucgua u

21

<210> SEQ ID NO 55  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 55

uccuggcuag gcaacaucau c

21

<210> SEQ ID NO 56  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 56

ugauguugcc uagccaggaa u

21

<210> SEQ ID NO 57  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 57

guggcaagua ccucuucaac u

21

<210> SEQ ID NO 58  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 58

uugaagaggu acuugccaca a

21

<210> SEQ ID NO 59  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 59

guggugccua cuccuacuuu c

21

<210> SEQ ID NO 60  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 60

aaguaggagu aggcaccaca u

21

<210> SEQ ID NO 61  
<211> LENGTH: 21  
<212> TYPE: RNA  
<213> ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 61

-continued

uugguggcuc caucuuagcc c	21
<210> SEQ ID NO 62	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 62	
gcuaagaugg agccaccaaa g	21
<210> SEQ ID NO 63	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 63	
cacggcuagc uugaaaagggu c	21
<210> SEQ ID NO 64	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 64	
ccuuucacag cuagccguga c	21
<210> SEQ ID NO 65	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 65	
ccgcuugacu gcagagagug c	21
<210> SEQ ID NO 66	
<211> LENGTH: 21	
<212> TYPE: RNA	
<213> ORGANISM: Hepatitis C virus	
<400> SEQUENCE: 66	
acucucugca gucaagcgac u	21
<210> SEQ ID NO 67	
<211> LENGTH: 29751	
<212> TYPE: DNA	
<213> ORGANISM: Severe acute respiratory syndrome virus	
<400> SEQUENCE: 67	
ttatttagtt ttaccttacc cagaaaaagc caacccaacct cgatctcttg tagatctgtt	60
ctcttaaacga actttaaaat ctgtgttagct gtgcgtcggt tgcatgccta gtgcacccatc	120
gcagtataaa caataataaaa ttttactgtc gttgacaaga aacgagtaac tcgtccctct	180
tctgcagact gcttacgggtt tcgtccgtgt tgcaagtcgt catcagcata ccttaggttc	240
gtccgggtgt gaccgaaagg taagatggag agccttgttc ttgggtgtcaa cgagaaaaca	300
cacgtccaac tcaagttgcc tgccttcag gtttagagacg tgcttagtgcg tggcttcggg	360
gactctgtgg aagaggccct atcggaggca cgtgaacacc tcaaaaatgg cacttgggt	420
ctagtagagc tggaaaaagg cgtactgccc cagcttgaac agccctatgt gttcattaaa	480
cgttctgtatg ccttaagcac caatcacggc cacaaggctcg ttgagctgg tgcagaaatg	540

-continued

---

gacggcattc agtacggtcg tagecggtata acactgggag tactcgtgcc acatgtggc	600
gaaaccccaa ttgcataccg caatgttctt ctgcgtaaaga acggtataaa gggagccgg	660
ggtcatacgat atggcatcga tctaaagtct tatgacttag gtgacgagct tggcactgat	720
cccatattaac attatgaaca aaactgaaac actaaggatg gcagtggtgc actccgtaa	780
ctcaactcgat agctcaatgg aggtgcagtc actcgctatg tcgacaacaa tttctgtggc	840
ccagatgggtt acccctttga ttgcataaaa gatttctcg cacgcgcggg caagtcaatg	900
tgcactctt ccgaacaact tgattacatc gagtcgaaga gaggtgtcta ctgctgcgt	960
gaccatgagc atgaaattgc ctggttact gagcgctctg ataagagcta cgagcacag	1020
acacccttcg aaattaagag tgccaagaaa tttgacactt tcaaaggggg atgcccgg	1080
tttgttctt ctcttaactc aaaagtcaaa gtcattcaac cacgtgttga aaagaaaaag	1140
actgagggttt tcatggggcg tatacgctct gtgtaccctg ttgcacatcc acaggagtg	1200
aacaatatgc acttgtctac cttgtatgaaa tgtaatcatt gcatgaaatg ttcatggcag	1260
acgtgcgact ttctgaaagc cacttgtgaa cattgtggca ctgaaaattt agttattgaa	1320
ggacctacta catgtgggtt cctacctact aatgctgttag tgaaaatgcc atgtcctgcc	1380
tgtcaagacc cagagattgg acctgagcat agtgttgcag attatcacaac ccactcaaac	1440
attgaaactc gactccgcaa gggaggttagg actagatgtt ttggaggctg tgggtttgcc	1500
tatgttggct gctataataa gcgtgcctac tgggttctc gtgtactgtc tgatattggc	1560
tcaggccata ctggcattac tggtgacaat gtggagacat tgaatgagga tctcctttag	1620
atactgagtc gtgaaacgtgt taacattaac attgttggcg attttcatggt gaatgaagag	1680
gttgccatca ttttggcatc tttctctgct tctacaagtg ccttatttga cactataaag	1740
agtcttgcattt acaagtcttt caaaaccatt gttgagtcctt gcggtaaacta taaagttacc	1800
aaggggaaagc ccgtaaaagg tgcttggaaat attggacaac agagatcgtt tttacacca	1860
ctgtgtgggtt ttccctcaca ggctgtgtt gttatcagat caattttgc ggcacactt	1920
gatgcagcaa accactcaat tcctgatttgc caaagagcag ctgtcaccat acttgcgtt	1980
atttctgaac agtcattacg tctgtcgac gccatggttt atacttcaga cctgtcacc	2040
aacagtgtca ttattatggc atatgttaact ggtgggtttt tacaacagac ttctcagtg	2100
ttgtctaatc ttttggcac tactgttggaa aaactcaggc ctatcttgc atggatgg	2160
gcgaaactta gtgcaggagt tgaatttctc aaggatgctt gggagattct caaatttctc	2220
attacaggtt ttttgcattt cgtcaagggtt caaatacagg ttgttgcaga taacatcaag	2280
gattgtgtaa aatgtttcat tggatgttggaa aacaaggcac tgcggaaatgtg cattgtatca	2340
gtcaactatcg ctggcgcaaa gttgcgtatca ctcaacttag gtgaaatctt catcgctca	2400
agcaaggac tttaccgtca gtgtatacgat ggcaaggagc agctgcaact actcatgcct	2460
cttaaggcac caaaaaggaaat aacctttttttaa gaaggttgcattt cacaatgcac agtacttacc	2520
tctgaggagg ttgttctcaaa gaacgggttcaaa ctgcgttgcac tgcggacgc cgttgcgtt	2580
ttcacaaatg gagctatcgat cggcacacca gtctgttggaa atggcctcat gctcttagag	2640
attaaggaca aagaacaata ctgcgttgcattt tctccttgggtt tactggctac aaacaatgtc	2700
tttcgtttaaa aagggggtgc accaattttttttaa ggtgttaacctt ttggagaaga tactgtttgg	2760
gaagttcaag gttacaagaa tggatgttggaa acatggatccg tttgtatggaaatggatgg	2820
gtgcttaatg aaaagtgttc tggatgttggaa atggatccg gtaccgaatgt tactgtttttt	2880
gcgtgttgc tggatgttggaa acatggatccg tttgtatggaaatggatgg	2940

-continued

---

aacatgggta ttgatcttga tgagtggagt gtagctacat tctacttatt tgatgtatgc	3000
ggtgaagaaa acttttcate acgtatgtat tgttcccttt accctccaga tgaggaaagaa	3060
gaggacgatg cagagtgtga ggaagaagaa attgatgaaa cctgtgaaca tgagtacggt	3120
acagaggatg attatcaagg tctccctctg gaatttggtg cctcagctga aacagttcga	3180
gttgaggaag aagaagagga agactggctg gatgatacta ctgagcaatc agagattgag	3240
ccagaaccag aacctacacc tgaagaacca gttaatcagt ttactggta tttaaaactt	3300
actgacaatg ttgccattaa atgtgttgc atcgtaagg aggccacaag tgctaattct	3360
atggtgattg taaatgctgc taacatacac ctgaaacatg gtgggttgtg agcaggtgca	3420
ctcaacaagg caaccaatgg tgccatgcaa aaggagatgt atgattacat taagctaaat	3480
ggccctttaa cagtaggagg gtcttgggg ctttctggac ataatcttc taagaagtgt	3540
ctgcatgttg ttggacctaa cctaaatgca ggtgaggaca tccagttct taaggcagca	3600
tatgaaaatt tcaattcaca ggacatctta cttgcaccat tgggtgtcgc agggcatattt	3660
ggtgctaaac oacttcagtc tttacaagtg tgcgtgcaga cggttcgtac acaggtttat	3720
attgcagtca atgacaagec tctttatgag caggtgtca tggattatct tgataacctg	3780
aagcctagag tggaaagcacc taaacaagag gagccaccaa acacagaaga ttccaaaact	3840
gaggagaat ctgtctgtaca gaagcctgtc gatgtgaagc caaaaattaa ggcctgcatt	3900
gatgaggtta ccacaacact ggaagaaact aagttctta ccaataagtt actcttgttt	3960
gtgtatca atggtaagct ttaccatgt tctcagaaca tgcttagagg tgaagatatg	4020
tcttccttg agaaggatgc accttacatg gtaggtgtatg ttatctactg tgggtatc	4080
acttgggtt taataccctc caaaaaggct ggtggcaact ctgagatgt ctcaagagct	4140
ttgaagaaag tgccagttga tgagtatata accacgtacc ctggacaagg atgtgttgt	4200
tatacacttg aggaagctaa gactgcttt aagaaatgca aatctgcatt ttatgtacta	4260
ccttcagaag cacctaattgc taaggaagag attcttagaa ctgtatccctg gaatttgaga	4320
gaaatgttg ctcatgctga agagacaaga aaattaatgc ctatatgcatt ggtgtttaga	4380
gccataatgg caaccatcca acgtaagtat aaaggaatta aaattcaaga gggcatcggt	4440
gactatgggt tccgattctt ctttatact agtaaagagc ctgtagctc tattattacg	4500
aagctgaact ctctaaatga gccgcttgc acaatgcca ttgggtatgt gacacatgg	4560
ttaatcttg aagaggctgc ggcgtgtatg cgttcttttta aagctcctgc cgtgtgtca	4620
gtatcatcac cagatgctgt tactacat aatggatacc tcacttcgtc atcaaagaca	4680
tctgaggagc actttttaga aacagttctt ttggctggc cttacagaga ttggccttat	4740
tcaggacagc gtacagagtt aggtgttggaa ttcttaagc gtgggtacaa aattgtgtac	4800
cacactctgg agagccccgt cgagtttcat cttgacgggt aggttcttc acttgacaaa	4860
ctaaagagtc tcttatccct gcgggaggtt aagactataaa aagtgttccac aactgtggac	4920
aacactaatac tccacacaca gcttggat atgtctatga catatggaca gcagtttgt	4980
coaacaacta tggatggc tcatgttaca aaaatataac ctcatgtaaa tcatgagggt	5040
aagactttct ttgtactacc tagtgtatgc acactacgtt gtgaagctt cgagttactac	5100
catactcttg atgagatgttt tcttggtagg tacatgtctg cttaaacca cacaagaaa	5160
tggaaatttc ctcaagttgg tggtttaact tcaattaaat gggctgatcaa aattgttgtat	5220
ttgtcttagtg ttttattagc acttcaacag cttgaagtca aattcaatgc accagcactt	5280

-continued

---

caagaggcctt attatagagc ccgtgctgggt gatgctgcta acttttgatgc actcataactc	5340
gcttacagta ataaaactgt tggegagctt ggtgatgtca gagaaactat gaccatctt	5400
ctacagcatg ctaatttggaa atctgcaaag cgagttctta atgtgggtgt taaacatgt	5460
ggtcagaaaa ctactacctt aacgggtgta gaagctgtga tgtatatggg tactctatct	5520
tatgataatc ttaagacagg tggttccatt ccatgtgtgt gtggctgtga tgctacacaa	5580
tatcttagtac aacaagagtcc ttctttgtt atgatgtctg caccacgtgc tgagtataaa	5640
ttacagcaag gtacattctt atgtgcgaaat gагtacactg gtaactatca gtgtggtcat	5700
taactctata taactgctaa ggagaccctc tаtсgttattg acggagctca ccttacaaag	5760
atgtcagatg acaaaggacc agtgaсtgtat gtttctaca aggaaacatc ttacactaca	5820
accatcaagc ctgtgtcgta taaaactcgat ggagttactt acacagagat tgaaccaaaa	5880
ttggatgggtt attataaaaaa ggataatgt tactatacag agcagccat agaccttgtat	5940
ccaactcaac cattaccaaa tgcgagttt gataattca aactcacatg ttctaacaca	6000
aaatttgctg atgatTTaaa tcaaattgaca ggcttcacaa agccagctc acgagagct	6060
tctgtcatac tcttcccaga cttgaatggc gatgtgtgg ctattgacta tagacactat	6120
tcagcgagtt tcaagaaagg tgctaaattt ctgcataagc caattgtttg gcacattaac	6180
caggctacaa ccaagacaac gttcaaaacca aacacttggt gtttacgttg tctttggagt	6240
acaaaggccag tagatacttc aaattcattt gaagttctgg cagtagaaga cacacaagga	6300
atggacaatc ttgcttgtat gagtcaacaa cccacctctg aagaagttagt ggaaaatcct	6360
accatacaga aggaagtcat agagtgtac gtgaaaacta ccgaagttgtt aggcaatgtc	6420
atacttaaac catcagatga aggtgttaaa gtaacacaag agttaggtca tgaggatctt	6480
atggctgctt atgtggaaaa cacaagcattt accattaaga aacctaattgtat gctttacta	6540
gccttaggtt taaaacaat tgccactcat ggtattgtctg caattaatag tggcttctgg	6600
agtaaaaattt tggcttatgt caaaccattt ttaggacaag cagcaattac aacatcaaat	6660
tgcgctaaga gattagcaca acgtgtgttt aacaattata tgccttatgt gtttacatta	6720
ttgttccaat tggcttatgtt tactaaaatg accaattcttta gaatttagagc ttcaactac	6780
acaactattt tggcttatgtt caaaccattt ttaggacaag cagcaattac aacatcaaat	6840
tgcgctaaga gattagcaca acgtgtgttt aacaattata tgccttatgt gtttacatta	6900
ttaagtattt gcttaggttc tctaattctgt gtaactgtctg ctttgggtt actcttatct	6960
aattttgggtt ctcccttctta ttgtatggc gtttagagaat tggatctttaa ttctgtctaa	7020
gttactacta tggatttctg tgaagggttctt ttcccttgca gcatgggtt aagtggatta	7080
gactcccttg attcttatcc agctcttggaa accattcagg tgacgatttc atcgtacaag	7140
ctagacttga caattttagg tctggccgtt gagttgggtt tggcatatat gttgttcaca	7200
aaattctttt atttatttagg tctttcagttt ataatgcagg tggctttgg ctatTTgt	7260
agtcatttca tcaatccatc ttggctcatg tggttatca ttagtattgtt acaaatggca	7320
cccggttctg caatgggttag gatgtacatc ttctttgtctt ctttctacta catatggaa	7380
agctatgttc atatcatggat tgggtgcacc tcttcgactt gcatgtgtg ctataagcgc	7440
aatcgtgcca cacgcgttga gtgtacaactt attgttaatg gcatgaagag atctttctat	7500
gtctatgtca atggaggccg tggcttctgc aagactcaca attggaaatgt tctcaatgt	7560
gacacatTTTt gcaactggtag tacattcattt agtgtatgtt tggctgtga ttgttcactc	7620
cagtttaaaa gaccaatcaa ccctactgtac cagtcatcgat atattgttga tagtggct	7680

-continued

gtgaaaaat ggcgcgttca cctctacttt gacaaggctg gtcaaaagac ctatgagaga 7740  
catccgcctc cccattttgt caatttagac aatttgagag ctaacaacac taaaggttca 7800  
ctgccttatta atgtcatagt ttttgatggc aagtccaaaat gegacgagtc tgcttctaa 7860  
tctgcttctg tgtactacag tcagctgatg tgccaaccta ttctgttgct tgaccaagct 7920  
cttgtatcg acgttggaga tagtactgaa gttccgtta agatgttga tgcttatgtc 7980  
gacacccccc cagcaacttt tagtgttccat atggaaaaac ttaaggact tgttgttaca 8040  
getcacagcg agtttagaaaaa ggggtgttagct ttagatggtg tctttctac attcggttca 8100  
gtgtccccggc aagggtttgt tgataccgt gttgacacaa aggtatgtt tgaatgtctc 8160  
aaactttcac atcactctga ctttagaagtg acagggtgaca gttgtaacaa tttcatgctc 8220  
acctataata aggttgaaaa catgacgccc agagatctt ggcgtatgtat tgactgtat 8280  
gcaaggcata tcaatgccca agtagcaaaa agtcacaaatg tttcaactcat ctggaatgt 8340  
aaagactaca tgtctttatc tgaacagctg cgtaaacaaa ttctgttagtgc tgccaaagaag 8400  
aacaacatac ctttttagact aacttgttgc tacaacttagac aggttgttca tgcataact 8460  
actaaaatct cactcaaggg tggtaagatt gtttagtactt gttttaaact tatgtttaag 8520  
gccacattat tgtcggttct tgctgcattt gttgttata tgcgttatgcc agtacataca 8580  
ttgtcaatcc atgtatggta cacaatgaa atcattggtt acaaaggccat tcaggatgg 8640  
gtcactcgatg acatcatttc tactgtatgat tgtttgcata ataaacatgc tgggtttgac 8700  
gcatggttta gccagcggtgg tggttcatac aaaaatgaca aaagctgccc tgcgttagct 8760  
gtctatcatttta caagagagat tggttcatac gtgcctgggt taccgggtac tgcgttgaga 8820  
gcaatcaatg gtgacttctt gcattttcta cctcgtgtt ttagtgcgt tggcaacatt 8880  
tgctacacac cttccaaact cattgagttt agtgattttgc taccctctgc ttgcgttctt 8940  
gctgctgatg gtacaatttt taaggatgtc atggggcaaaat ctgtggccata ttgtttagac 9000  
actaatttgc tagagggttc tatttcttata agtgagcttgc gtccagacac tgcgttatgt 9060  
ctttagggatg gttccatcat acagtttccat aacacttacc tggagggttc tggtaggt 9120  
gtaacaactt ttgatgttgc gtactgttgc catggatcat gcaagggttc agaagtaggt 9180  
atttgccatctt ctaccatgttgg tagatgggtt ctttataatg agcattacag agctctatca 9240  
ggagttttctt gtgggtttga tgcgtatgttgc ctcatatgtt acatcttgc tcccttgc 9300  
caacccgtgg gttccatgttgc tgcgtatgttgc tgcgtatgttgc tgggtttgtt tatttgc 9360  
ttgggtgactt gtgcgttgcctt ctactttatg aaattcagac gtgttttgg tgagttttttt 9420  
catgttgcgttgc tgcgtatgttgc acctttgtttt ttgtatgttgc tcaactatgtt ctgtgttgc 9480  
ccagcttaca gttttcttgc gggaggcttac tcagttttt acctgttactt gacatttctt 9540  
tttccatgttgc atgttttcat tttgggttgc ctcaatgttgc tggccatgtt ttcttgc 9600  
gtgcctttttt ggataacagc aatctatgttgc ttctgttattt ctctgttgc ctgcattttt 9660  
ttcttgcata actatcttgc gaaaagggttgc atgtttatgttgc gagtttacattt tagtaccc 9720  
gggggggttgc ctgggtttgc ttttttgc ttttttgc ttttttgc ttttttgc ttttttgc 9780  
gagacactgt tgccacttac acagtataac aggtatcttgc ctctatataa caagttttttt 9840  
tatttttttttttgc ttttttgc ttttttgc ttttttgc ttttttgc ttttttgc ttttttgc 9900  
aaggctctaa atgacttttttgc caactcaggt gctgtatgttgc tctaccaacc accacagaca 9960  
tcaatcactt ctgtgttgc ttttttgc ttttttgc ttttttgc ttttttgc ttttttgc ttttttgc 10020

-continued

---

gttgaagggt gcatggtaca agtaacctgt ggaactacaa ctcttaatgg attgtgggtg 10080  
 gatgacacag tatactgtcc aagacatgtc atttgcacag cagaagacat gcttaatcct 10140  
 aactatgaag atctgtcat tcgcaaatcc aaccatagct ttcttggtca ggctggcaat 10200  
 gttcaacttc gtgttattgg ccattctatg caaaattgtc tgcttaggct taaagttgat 10260  
 acttctaacc ctaagacacc caagtataaa tttgtccgtt tccaaacctgg tcaaaccatt 10320  
 tcagttctag catgtacaa tggttcacca tctggtgttt atcagtgtgc catgagacct 10380  
 aatcatacca ttaaagggtc tttccttaat ggatcatgtg gtagtgttgg ttttaacatt 10440  
 gattatgatt gcgtgtctt ctgctatatg catcatatgg agcttccaac aggagtagac 10500  
 gctggtaactg acttagaagg taaaattctat ggtccatttg ttgacagaca aactgcacag 10560  
 gctgcaggta cagacacaac cataacatta aatgttttg catggctgt tgcgtctgtt 10620  
 atcaatggtg ataggtgggt tcttaataga ttcaccacta ctttgaatga ctttaacatt 10680  
 gtggcaatga agtacaacta tgaacccttg acacaagatc atgttgacat attgggacct 10740  
 ctttctgctc aaacaggaat tgccgtctta gatatgtgtg ctgctttgaa agagctgtg 10800  
 cagaatggta tgaatggtcg tactatcctt ggttagacta ttttagaaga tgagttaca 10860  
 ccatttgatg ttgttagaca atgctctgtt gttaccttcc aaggttaagtt caagaaaatt 10920  
 gttaagggc ctcatcattt gatgtttta actttcttga catcactatt gattctgtt 10980  
 caaagtacac agtggtaact gttttcttt gtttacgaga atgctttctt gccatttact 11040  
 ctgggtatta tggcaattgc tgcatgtgt atgctgtttt ttaagcataa gcacgcattc 11100  
 ttgtgcttgt ttctgttacc ttctcttgc acagttgtt actttaatat ggtctacatg 11160  
 cctgcttagct gggtgatgct tatcatgaca tggcttgaat tggctgacac tagctgtct 11220  
 ggttataggc ttaaggattt tggttatgtat gcttcagctt tagttttgtt tattctcatg 11280  
 acagctcgca ctgtttatga ttagtgcgtt agacgtgttt ggacactgtat gaatgtcatt 11340  
 acacttgc tacaaggctt ctatggtaat gcttttagatc aagcttatttc catgtgggcc 11400  
 ttagttatcc tggtaaccc ttaactattttt ggtgtcgta cgactatcat gtttttagct 11460  
 agagctatag tgggtgtt tggtagtacat tttttttt tttttttt tggcaacacc 11520  
 ttacagtgtt tcatgtttt ttattgtttt ttaggttattt gttgtgtgt ctactttggc 11580  
 cttttctgtt tactcaaccg ttacttcagg cttaactttt gttttatgtt ctacttggc 11640  
 tctacacaag aatttaggtt tatgaactcc caggggttt tgcctctaa gagtagtatt 11700  
 gatgtttca agcttaacat taatgtttt ggtattggag gtaaaccatg tatcaagggtt 11760  
 getactgtac agtctaaaat gtctgacgtt aagtgacat ctgtggtaact gctctcggtt 11820  
 cttcaacaac ttagagtaga gtcattttttaaa aaattgtggg cacaatgtgtt acaactccac 11880  
 aatgatattt ttcttgcaaa agacacaactt gaaagtttcg agaagatggt ttctttttt 11940  
 tctgttttgc tatccatgca ggggtgttca gacattaataa ggttgtgcga ggaaatgtc 12000  
 gataaccgtt ctactttca ggcttattgtt tcagaatttta gttctttacc atcatatgcc 12060  
 gcttatgccca ctgcccaggaa ggcctatgag caggctgttag ctatggtga ttctgaagtc 12120  
 gttctcaaaa agttaaagaa atctttgtt gttgtttttt gttgtgttgcgatgttgc 12180  
 gccatgcaac gcaagggtt gaaagatggca gatcaggctt tgacccaaat gtacaaacag 12240  
 gcaagatctg aggacaagag ggcaaaatgtt acttagtgcata tgcacaaat gcttttact 12300  
 atgcttaggtt agcttgataa ttagtgcactt aacaacattt tcaacaaatgc gctgtatgtt 12360  
 tttgtgttccac tcaacatcat accattgtactt acagcagccaa aactcatgtt tttgttccct 12420

-continued

---

gattatggta octacaagaa cacttgtat ggtAACACCT ttacatatgc atctgcactc 12480  
 tgggaaatcc agcaaggtagt tgatcgaggat agcaagatgg ttcaacttag tgaaattaac 12540  
 atggacaatt caccaaattt ggcttggcct cttattgtta cagctctaag agccaactca 12600  
 gctgttaaac tacagaataa tgaactgagt ccagtagcac tacgacagat gtcctgtgcg 12660  
 gctggtagcca cacaaacagc ttgtactgtat gacaatgcac ttgcctacta taacaattcg 12720  
 aaggggaggtt ggtttgtct ggcattacta tcagaccacc aagatctcaa atgggctaga 12780  
 ttccctaaga gtgatggtagt aggtacaatt tacacagaac tggAACCCAC ttgtaggTTT 12840  
 gttacagaca cacaaaagg gcctaaagtgg aaataacttgc acttcataaaggcttaac 12900  
 aacctaaata gaggtatggt gctggcagt ttagctgcta cagtagtct tcaggctgga 12960  
 aatgtctacag aagtacctgc caattcaact gtgcTTTCTC tctgtgtttt tgcaGAGAC 13020  
 cctgctaaag catataagga ttaccttagca agtggaggac aaccaatcac caactgtgt 13080  
 aagatgttgtt gtacacacac tggtagcaggaa caggcaattt ctgttaacacc agaagctaac 13140  
 atggaccaag agtcctttgg tggtgcttca tggtagtctgtt attgttagatg ccacattgac 13200  
 catccaaatc ottaaggatt ctgtgacttg aaaggtaagt acgtccaaat acctaccact 13260  
 tggtagtctatg acccagtggg ttttacactt agaaacacag tctgtaccgt ctgcggaaatg 13320  
 tggaaagggtt atggctgttag tggtagccaa ctccgcgaac ctttgcgttgc gtctgcggat 13380  
 gcatcaacgt ttttaaacgg gtttgcgggtg taagtgcaggc ccgtcttaca ccgtgcggca 13440  
 caggcactag tactgtatgtc gtctacagggtt ctttgcgttgc ttacaacggaa aaaggtagt 13500  
 gttttgcggaa gttcctaaaa actaattgtt gtgcgttcca ggagaaggat gaggaaggca 13560  
 atttatttgcgtt ctcttacttt gtatgttgc ggcataactat gtcttaactac caacatgtt 13620  
 agactatttgcgtt aaagattgtc cagcggttgc tggccatgtac ttttcaagt 13680  
 ttagagtaga tggtagatg gtaccacata tatcactgtca gctgttactaaatcacaa 13740  
 tggctgatattt agtctatgtt ctactgttgc ttgtatgggg taattgtatg acattaaag 13800  
 aaataactcggtt cacatacaat tgctgtatg atgattttt caataagaag gattggatgt 13860  
 acttcgttgcgtt gaatcctgtac atcttacggc tatatgttgc cttaggttgc cgttacgccc 13920  
 aatcattattt aaagactgtt caattctggcgtt atgctatgtc tgatgcaggc attgttagggc 13980  
 tactgtatggtt agataatcgat gatcttgcgtt ggaactggta cgatttcgggtt gatttcgtt 14040  
 aagtagcacc aggctgcggaa gtttgcgttgc ttgtatgttgc ttactgttgc ctgtatgttgc 14100  
 tcctcactttt gactaggggca ttggctgttgc agtcccataat ggtatgttgc ctgcggaaac 14160  
 cacttattaa gtgggatggc ttgtatgttgc ttgtatgttgc ttactgttgc ctgtatgttgc 14220  
 accgttattt taaatattgg gaccagacat accatccaaat ttgtatgttgc ttgtatgttgc 14280  
 atagggttatgtt ctttgcgttgc ttgtatgttgc ttactgttgc ttgtatgttgc ttgtatgttgc 14340  
 caagttttgg accactgttgc agaaaaatat ttgtatgttgc ttgtatgttgc ttgtatgttgc 14400  
 ctggataccaa ttttgcgttgc ttgtatgttgc tacataatgttgc ggtatgttgc ttacataatgttgc 14460  
 cgcgttgcgtt ctttgcgttgc ttgtatgttgc ttactgttgc ttgtatgttgc ttgtatgttgc 14520  
 ctggcaattt attgtatgttgc aaacgcacta catgttttgcgttgc ctaacaaaca 14580  
 atgtttgtttt tcaaaactgttgc aaacccggta attttataaa agactttat gactttgttgc 14640  
 ttttgcgttgc ttgtatgttgc ttgtatgttgc ttactgttgc ttgtatgttgc ttgtatgttgc 14700  
 aggtatggccaa cgcgttgcgttgc ttgtatgttgc ttactgttgc ttataatgttgc ccaacaaatgttgc 14760

-continued

-continued

---

gaatcataacc tgccgtgcg cgcgtagagt gtttgataa attcaaagtg aattcaacac 17220  
 tagaacatgtgttctgc actgtaaatg cattgccaga aacaactgtc gacattgtag 17280  
 tctttgtatga aatctctatg gctactaatt atgacttgag tggtgtcaat gctagactc 17340  
 gtgcacaaaca ctacgtctat attggcgatc ctgctcaatt accagcccc cgcacattgc 17400  
 tgactaaagg cacactagaa ccagaatatt ttaattcagt gtgcagactt atgaaaacaa 17460  
 taggtccaga catgttcctt ggaacttgcg gccgttgtcc tgctgaaatt gttgacactg 17520  
 tgagtgtttt agtttatgac aataagctaa aagcacacaa ggataagtc gctcaatgt 17580  
 tcaaaatgtt ctacaaaggt gttattacac atgatgtttc atctgcaatc aacagacctc 17640  
 aaataggcgt tgtaagagaa ttctttacac gcaatcctgc ttggagaaaa gctgtttta 17700  
 ttcacaccca taattcacag aacgctgttag ctccaaaaat cttaggattt cctacgcaga 17760  
 ctgttgattt atcacagggt tctgaatatg actatgtcat attcacacaa actactgaaa 17820  
 cagcacaccc ttgtaatgtc aaccgcttca atgtggctat cacaaggcga aaaattggca 17880  
 ttttgtcat aatgtctgtat agagatcttt atgacaaact gcaatttaca agtctagaaa 17940  
 taccacgtcg caatgtggct acattacaag cagaaaaatgt aactggactt tttaaggact 18000  
 gtagtaagat cattactggt ctccatccta cacaggcacc tacacaccc agcgttgata 18060  
 taaagttcaa gactgaagga ttatgtgtt acataccagg cataccaaag gacatgacct 18120  
 accgttagact catctctatg atgggtttca aaatgaatta ccaagtcaat ggttacccta 18180  
 atatgtttt cacccgcgaa gaagttttc gtcacgttcg tgctgtggatt ggctttgtg 18240  
 tagagggctg tcatgcaact agagatgtg tgggtactaa cttacccctc cagctaggat 18300  
 ttcttacagg tgtaactta gtatgttac cgactggttt tggtgacact gaaaataaca 18360  
 cagaattcac cagagttaat gcaaaaccc caccaggtaa ccagttaaa catttatac 18420  
 cactcatgtt taaaggctt cccttggatg tagtgcgtat taagatagta caaatgctca 18480  
 gtgatacact gaaaggattt tcagacacag tcgtgttcgt cttttggcg catggttt 18540  
 agcttacatc aatgaagtac ttgttcaaga ttggacactga aagaacgtgt tgcgtgtgt 18600  
 acaaacgtgc aacttgcattt tctacttcat cagatactta tgcctgctgg aatcattctg 18660  
 tgggttttga ctatgtctat aaccatata tgattgtat tcagcagtgg ggctttacgg 18720  
 gtaacccatca gagtaaccat gaccaacatt gccaggatca tggaaatgca catgtggct 18780  
 gttgtgtgc tatcatgact agatgtttt cagttcatg tgctgtttt aagcgcgtt 18840  
 attggctgt tgaataccct attataggag atgaactgag ggttaattct gtttgcagaa 18900  
 aagtacaaca catggttgtg aagtctgtat tgctgtca taagttcca gtttccatg 18960  
 acattggaaa tccaaaggct atcaagtgtg tgcctcaggc tgaagtagaa tggaaatgt 19020  
 acatgtgtca gccatgttgt gacaaagctt acaaaataga ggaactcttc tattttatg 19080  
 ctacacatca cgataaattt actgatggtg ttgtttttt ttggaaattgt aacgttgatc 19140  
 gttaccaccc caatgcaatt gtgtgttagt ttgacacaag agtcttgcata aacttgaact 19200  
 taccaggctg tgatgtgtt agtttgcattt tgcattccac actccagtt 19260  
 tcgataaaag tgcattttact aatttaaagc aattgcctt cttttactat tctgatagtc 19320  
 cttgtgtgtc tcatggccaa caagtagtgtt cggatattga ttatgttcca ctcaaatctg 19380  
 ctacgtgtat tacacgtatc aatttaggtt gtcgtgtttt cagacaccat gcaaatgtt 19440  
 accgacagta cttggatgca tataatatga tgatttgc tggatattgc ctatggattt 19500

-continued

---

acaaacaatt tgatacttat aacctgtgga atacattac caggttacag agtttagaaa 19560  
 atgtggctta taatgttgtt aataaaggac actttgtatgg acacgcggc gaagcacctg 19620  
 tttccatcat taataatgct gtttacacaa aggttagatgg tattgtatgtg gagatcttg 19680  
 aaaataagac aacacttcct gttaatgtt catttgagct ttgggtaag cgtaacatta 19740  
 aaccagtgcc agagatthaag atactcaata atttgggtgt tgatatcgct gctaatactg 19800  
 taatctggaa ctacaaaaga gaagccccag cacatgtatc tacaataggt gtctgcacaa 19860  
 tgactgacat tgccaagaaaa cctactgaga gtgcttggc ttcacttact gtctgttg 19920  
 atggttagagt ggaaggacag gtacacccc tttagaaacgc ccgtatggt gtttaataa 19980  
 cagaagggttc agtcaaaggt ctaacaccc caaagggacc agcacaagct agcgtcaatg 20040  
 gagtcacatt aattggagaa tcagtaaaaa cacagttaa ctactttaag aaagttagacg 20100  
 gcattattca acagttgcct gaaacctact ttactcagag cagagactta gaggattta 20160  
 agcccgatc acaaatggaa actgacttcc tcgagctcg tatggatgaa ttcatacagc 20220  
 gatataagct cgagggctat gccttcgaac acatcggttta tggagatttc agtcatggac 20280  
 aacttggcgcc tcttcattta atgataggct tagccaagcg ctcacaagat tcaccactta 20340  
 aatttagagga ttttatccct atggacagca cagtgaaaaaa ttacttcata acagatgcgc 20400  
 aaacagggttc atcaaaatgt gtgtgttctg tgattgtatc tttacttgat gactttgtcg 20460  
 agataataaa gtcacaagat ttgtcagtga ttcaaaaagt ggtcaagggtt acaattgact 20520  
 atgctgaaat ttcattcatg ctttgggtta aggatggaca tggtaaacc ttctaccctaa 20580  
 aactacaagc aagtgcgagcg tggcaaccag gtgttgcgt gccttaacttg tacaagatgc 20640  
 aaagaatgct tcttgaaaag tggcacccctc agaattatgg tgaaaatgct gttataccaa 20700  
 aaggaataat gatgaatgtc gcaaagtata ctcaactgtg tcaataactt aatacactta 20760  
 cttagctgt accctacaac atgagagttt ttcactttgg tgctggctct gataaaggag 20820  
 ttgcaccagg tacagctgtg ctcagacaat gggtgccaac tggcacacta cttgtcgatt 20880  
 cagatcttaa tgacttcgtc tccgacgcattt aattggagac tggtaaacc 20940  
 tacatacggc taataaatgg gaccttata tttagcgatgt gtatgaccctt aggaccaaac 21000  
 atgtgacaaa agagaatgtc tctaaagaag ggttttcac ttatctgtt ggatttataa 21060  
 agcaaaaact agccctgggt gggttctatag ctgtaaagat aacagagcat tcttgaaatg 21120  
 ctgaccttta caagctttagt ggccatttct catggtgac agctttgtt acaaatgtaa 21180  
 atgcacatc atcggaaagca ttttaatttgg gggcttaactt tcttggcaag ccgaagggaaac 21240  
 aaattgtatgg ctataccatg catgctaactt acatttctg gaggaacaca aatcctatcc 21300  
 agttgttcc ctattcaactt tttgacatgtca gcaaatttcc tctttaatggt agggaaactg 21360  
 ctgtaatgtc tcttaaggag aatcaaatgtca atgatatgtat ttattcttctt ctggaaaaag 21420  
 gtaggcttat catttagagaa aacaacagag ttgtgggttcc aagtgtatattt ctgtttaaca 21480  
 actaaacgaa catgtttattt ttcttactctt cactgtgtt agtgcaccc 21540  
 accgggtgcac cactttgtat gatgttcaag ctcttaattt cactcaacat acttcatcta 21600  
 tgaggggggtt ttaactatccctt gatgaaatttt tttagatcaga cacttttat ttaactcagg 21660  
 atttatttctt tccatTTTt tcttaatgttca cagggtttca tactttaat catacgttt 21720  
 gcaaccctgtt cataccctttt aaggatggta ttatTTTgc tgccacagag aatacaatg 21780  
 ttgtccgtgg ttgggtttt gggttctacca tgaacaacaa gtcacagtcg gtgatttataa 21840  
 ttaacaatttca tactaatgtt gttatacggcatgttaactt tgaattgtgtt gacaaccctt 21900

-continued

tctttgtgt ttctaaaccc atgggtacac agacacatac tatgatattc gataatgcat 21960  
 ttaattgcac ttgcaggtac atatctgatg cctttcgct tgatgttca gaaaagtctag 22020  
 gtaatttaa acacttacga gagtttgtt taaaaataa agatgggtt ctctatgtt 22080  
 ataagggcta tcaacccata gatgttagtc gtgatctacc ttctggttt aacactttga 22140  
 aacctatccc taagttgcct cttggattt acattacaaa ttttagagcc attcttacag 22200  
 cctttcacc tgctcaagac atttggggca cgtagctgc agcctatccc gttggctatt 22260  
 taaagccaaac tacatttatg ctcaagtatg atgaaaatgg tacaatcaca gatgtgtt 22320  
 attgttctca aaatccactt gctgaactca aatgctctgt taagagctt gagattgaca 22380  
 aaggaattta ccagacctct aatttcaggg ttgtccctc aggagatgtt gtgagattcc 22440  
 ctaatattac aaacttgcgt cctttggag aggtttttaa tgctactaaa ttcccttctg 22500  
 tctatgcattt ggagagaaaa aaaatttcta attgtgttgc tgattactct gtgctctaca 22560  
 actcaacatt ttttcaacc tttaagtgtt atggcgtttgc tgccactaag ttgaatgatc 22620  
 tttgcttctc caatgtctat gcagattctt ttgttagtcaa gggagatgtt gtaagacaaa 22680  
 tagcgcagg acaaaactggt gttattgtctt attataatta taaattgcca gatgattca 22740  
 tgggttgtgt octtgcttgg aataacttagga acattgtatgc tacttcaact ggttaattata 22800  
 attataaata taggtatctt agacatggca agcttaggc ctttggagaga gacatatcta 22860  
 atgtgecttt ctccccgtat ggcaaacctt gcacccccc acc tgctcttaat tgttattggc 22920  
 cattaaatga ttatggttt tacaccacta ctggcattgg ctaccaacct tacagagtt 22980  
 tagtactttc ttttgaactt tttaatgcac cggccacggt ttgtggacca aaattatcca 23040  
 ctgacccctt taagaaccag tgtgtcaatt ttatggttttaa tggactcaact ggtactgg 23100  
 tgtttaactcc ttcttcaaag agattcaac cattcaaca atttggccgt gatgtttctg 23160  
 atttcactga ttccgttca gatctaaaa catctgaaat attagacatt tcacccgtcg 23220  
 cttttgggg tgtaagtgtt attacacctg gaacaaatgc ttcatctgaa gttgtgttgc 23280  
 tataatcaaga tgtaactgc actgatgttt ctacagcaat tcatgcagat caactcacac 23340  
 cagcttggcg catatattct actggaaaca atgtattcca gactcaagca ggctgtctt 23400  
 taggagctga gcatgtcgac acttcttgc agtgcgacat tcctattggc gctggcattt 23460  
 gtgctagttt ccatacagtt tctttattac gtagtacttag ccaaaaatctt attgtggctt 23520  
 atactatgtc tttaggtgtt gatagttca ttgcttacttcaataacacc attgttatac 23580  
 ctactaactt ttcaatttgc attactacag aagtaatgcc ttgttctatg gctaaaacct 23640  
 ccgttagattt taatatgtac atctgcggag attctactga atgtgttaat ttgcttctcc 23700  
 aatatggtag cttttgcaca caactaaatc gtgcactctc aggtattgtt gctgaacagg 23760  
 atcgcaacac acgtgaagtgc ttgcgtcaag tcaaacaatgtt gtaaaaaacc ccaactttga 23820  
 aatattttgg tgggtttat ttccacaaa tattacctga ccctctaaag ccaactaaga 23880  
 ggtctttat tgaggacttg ctcttataa aggtgacact cgctgtatgtt ggcttcatga 23940  
 agcaatatgg ogaatgccta ggtgtatata atgcttagaga totcattttgtt ggcagaagt 24000  
 tcaatggact tacagtgttgc ccacccctgc tcactgtatgatgatgttgc gcctacactg 24060  
 ctgctctatgt tagtggactt gccactgtgc gatggacattt tggtgttgc gctgtcttc 24120  
 aaataccctt tgctatgcaaa atggcatata ggttcaatgg cattggagtt acccaaaaatg 24180  
 ttctctatga gaaccaaaaaa caaatcgcca accaattttaa caaggcgatt agtcaaattc 24240

-continued

---

aagaatcaactacaaca tcaactgcat tggccaagct gcaagacgtt gttaaccaga 24300  
 atgctcaagc attaaacaca cttgttaaac aacttagctc taattttgtt gcaatttcaa 24360  
 gtgtgtctaaa tgatatccct tcgctacttg ataaagtcta ggcggaggta caaattgaca 24420  
 ggtaattac aggcagactt caaaggcttc aaacctatgt aacacaacaa ctaatcaggg 24480  
 ctgctgaaat cagggtttct gctaattctt ctgctactaa aatgtctgag tgtgttctt 24540  
 gacaatcaa aagagttgac ttttgtggaa agggctacca ctttatgtcc ttcccacaag 24600  
 cagccccgca tgggtttgtc ttcctacatg tcacgtatgt gccatcccag gagaggaact 24660  
 tcaccacagc gccagcaatt tgcataatgaa gcaaagcata cttccctcgtaa gaagggtttt 24720  
 ttgtgtttaa tggcacttct tggtttatta cacagaggaa cttttttctt ccacaataa 24780  
 ttactacaga caatacattt gtctcaggaa attgtgtatgt cgttattggc atcattaaca 24840  
 acacagttta tgatcctctg caacctgagc ttgactcattt caaagaagag ctggacaagt 24900  
 acttcaaaaa tcatacatca ccagatgtt atcttggcgca catttcaggc attaacgctt 24960  
 ctgtcgtcaa cattcaaaaa gaaattgacc gcctcaatgaa ggtcgtctaa aatttaatg 25020  
 aatcactcat tgaccttcaa gaattggaa aatatgagca atatattaaa tggccttgg 25080  
 atgtttggct cggcttcatt gctggactaa ttgccatcgat catggttaca atcttgcctt 25140  
 gttgcatgac tagttgttgc agttgcctca agggtgcatg ctcttgtggt tcttgctgca 25200  
 agtttcatgaa ggatgactct gagccagttc tcaagggtgt caaattacat tacacataaa 25260  
 cgaacttatgattttt tgagatttt tactcttggca tcaattactg cacagccagt 25320  
 aaaaatttgc aatgttctc ctgcaagtac tgatcgatgtt acagcaacga taccgctaca 25380  
 agectcaactc ctttcggat ggcttggat tggcggttca tttcttgcgt ttttcagag 25440  
 cgctaccaaa ataatttgc tcaataaaaatg atggcagctt gcccatttttta agggcttcca 25500  
 gttcatttgc aatttacttgc tgatcgatgtt taccatctat tcaatcgat tgcatttgc 25560  
 tgcaggatgtt gaggcgcaat ttttgcattt ctatgccttgc atatatttttcaatgc 25620  
 caacgcattgtt agaatttattt tgagatgttgc gctttgttgg aagtgcattt ccaagaaccc 25680  
 attacttttgcatgcaact actttgttttgc ctggcacaca cataactatg actactgtat 25740  
 accatataaac agtgcacatg atacaattttgc tgcatttttttgc tttcaacacc 25800  
 aaaaactcaaa gaagactacc aaatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 25860  
 agactatgttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 25920  
 aatttactaca gacactggta ttgaaaatgc tacatttttgc atcttttgc ttttgcatttgc 25980  
 agacccaccg aatgtgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26040  
 aatggatcca atttatgttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26100  
 aagtgcatttttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26160  
 tagcgttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26220  
 tgcgttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26280  
 ggtttacgttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26340  
 ggtctaaacg aactaactat tatttttttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26400  
 gcaagacaacg gtactatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26460  
 gtaatagtttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26520  
 aacagggttttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26580  
 gtttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc 26640

-continued

---

gcaatggctt gtattgtagg cttgatgtgg cttagctact tcgttgcttc cttcaggctg 26700  
 tttgcgtcta cccgctcaat gtggtcattc aacccagaaa caaacattct tctcaatgtg 26760  
 cctctccggg ggacaattgt gaccagacgg ctcatggaaa gtgaacttgt cattggtgct 26820  
 gtgatcattc gtggtcactt gcaaatggcc ggacactccc tagggcgctg tgacattaag 26880  
 gacctgccaa aagagatcac tgtggctaca tcacgaacgc tttcttattta caaatttagga 26940  
 gcgtcgcagc gtgttaggcac tgattcaggt tttgctgcat acaaccgcta ccgttattgga 27000  
 aactataat taaatacaga ccacgcccgt agcaacgaca atattgctt gctagtacag 27060  
 taagtgacaa cagatgttgc atcttggta cttccaggtt acaatagcag agatattgat 27120  
 tatcattatg aggactttca ggattgctat ttggaatctt gacgttataa taagttcaat 27180  
 agtgagacaa ttatthaagc ctctaaactaa gaagaattat tccggagttag atgatgaaga 27240  
 acctatggag ttagattatc cataaaacga acatgaaaat tattctcttc ctgacattga 27300  
 ttgttattac atcttgcgag ctatatactt atcaggagtg tggtagaggt acgactgtac 27360  
 tactaaaaga accttgcaca tcaggaacat acgagggcaa ttcaccattt caccctttg 27420  
 ctgacaataa atttgcacta acttgcacta gcacacactt tgctttgtc tgcgtgcacg 27480  
 gtactcgaca taccttatcag ctgggtgcaaa gatcagttt accaaaaactt ttcatcagac 27540  
 aagaggaggt tcaacaagag ctctactcgc cacttttctt cattgttgc gctctagat 27600  
 ttttaataact ttgcttcacc attaagagaa agacagaatg aatgagctca ctttaatgt 27660  
 ctcttatttgc tgcttttag cctttctgtt attccttgc ttaataatgc ttattatatt 27720  
 ttggtttca ctgaaatcc aggtatctaga agaaccttgc accaaaagtct aaacgaacat 27780  
 gaaacttcttca attgtttgc cttgttatttgc tctatgcgt tgcatatgca ctgtgttaca 27840  
 ggcgttgca tctataaaac ctcatgtgt tgaagatcct tgcgttgc aacactaggg 27900  
 gtaataacttta tagcactgtgt tggctttgtc ctcttagggaa gttttacact tttcatagat 27960  
 ggcacactat ggttcaaaca tgcacacca atgttactat caactgtcaa gatccagctg 28020  
 gtgggtgcgtctatgttgc tggttgcgttcc ttcatgttgc tccatgttgc gctgttgc 28080  
 gagacgtact tggttgcgttca aataaacgaa caaattaaaaa tgcgttgc tggacccaa 28140  
 tcaaaaccaac gtagtgcggcc ccgcattaca ttgggtggac ccacagatcc aactgacaat 28200  
 aaccagaatg gaggacgcaaa tggggcaagg cccaaacagc gccgacccca aggtttaccc 28260  
 aataataactg cgtcttgcgtt cacagcttc actcagcatg gcaaggagga acttagattc 28320  
 cctcgaggcc agggcggtcc aatcaacacc aatagtggtc cagatgacca aattggctac 28380  
 taccgaagag ctacccgacg agttcggtt ggtgacggca aatgaaaga gctcagcccc 28440  
 agatggtaact tctattaccc tggactgtgc ccagaagctt cacttccctt cggcgctaac 28500  
 aaagaaggca tcgtatgggt tgcaactgtgg ggagcccttgc atacacccaa agaccacatt 28560  
 ggcacccgca atcctaataa caatgtgtcc accgtgttac aacttccctca aggaacaaca 28620  
 ttgccaaaag gcttctacgc agagggaaagc agaggcggca gtcaagccctc ttctcgctcc 28680  
 tcaatcactgttgc tgcgtggtaa ttcaatggaaat tcaactctgttgc gcaatgttgc 28740  
 cctgctcgaa tggcttagcg aggtgggttgc actggccctcg cgctattgttgc gcttagacaga 28800  
 ttgaaccacgc ttgagacaa agtttctgttgc aaaggccaa acacacaagg cccaaactgtc 28860  
 actaagaatat tgcgtgttgc ggcacatcttcaaa aacccctcgcc aaaaacgtac tgccacaaaa 28920  
 cagttacaacg tcactcaagc atttgggaga cgtggtccag aacaaacccca agggaaatttc 28980

-continued

---

```

ggggaccaag acctaatacg acaaggaact gattacaacat attggccgca aattgcacaa 29040
tttgctccaa gtgcctctgc attctttgga atgtcacgca ttggcatgga agtcacacct 29100
tcggAACAT ggctgactta tcatggagcc attaaattgg atgacaaaga tccacaattc 29160
aaagacaacg tcatactgct gaacaagcac attgacgcat aaaaaacatt cccaccaaca 29220
gagcctaaaa aggacaaaaaa gaaaaagact gatgaagotc agcccttgc gcagagacaa 29280
aagaagcgc ccactgtgac tcttcttctt gggctgaca tggatgattt ctccagacaa 29340
cttcaaaattt ccatgagtgg agcttctgtt gattcaactc aggcataaac actcatgtt 29400
accacacaag gcagatgggc tatgtaaacg tttcgcaat tccggttacg atacatagtc 29460
tactcttgtt cagaatgaat tctcgtaact aaacagcaca agtaggttta gttaacttta 29520
atctcacata gcaatcttta atcaatgtgt aacattaggg aggacttggaa agagccacca 29580
cattttcattt gagggccacgc ggagtacgtt cgagggtaca gtgaataatg cttagggagag 29640
ctgcctatat ggaagagccc taatgtgtaa aattaattttt agtagtgcta tccccatgtt 29700
attttaatag cttcttagga gaatgacaaa aaaaaaaaaa aaaaaaaaaa a 29751

```

&lt;210&gt; SEQ ID NO 68

&lt;211&gt; LENGTH: 21

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 68

cuuacgcuga guacuucgau u

21

&lt;210&gt; SEQ ID NO 69

&lt;211&gt; LENGTH: 21

&lt;212&gt; TYPE: RNA

&lt;213&gt; ORGANISM: Hepatitis C virus

&lt;400&gt; SEQUENCE: 69

ucgaaguacu cagcguagu u

21

---

40

What is claimed is:

**1.** A composition comprising a siRNA to HCV, comprising a first strand and a second strand, wherein the sequence of said first strand is the sequence of SEQ ID NO: 46.

**2.** The composition of claim 1, wherein the siRNA comprises at least one modification at the 2' position of at least one ribonucleotide.

**3.** The composition of claim 1, wherein said siRNA comprises at least one modification selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.

**4.** The composition of claim 3, wherein said fluoro-modification is a 2'-fluoro-modification or a 2',2'-difluoro-modification.

**5.** The composition of claim 1, wherein at least one pyrimidine of said siRNA is modified.

**6.** The composition of claim 1, wherein both strands of said siRNA contain at least one modified nucleotide.

**7.** A method for inactivating Hepatitis C Virus (HCV) in a patient, the method comprising the step of administering to said patient a siRNA in an amount effective to inactivate said virus, wherein said siRNA comprises a first strand and a second strand,

wherein the sequence of said first strand is the sequence of SEQ ID NO: 46 and/or the sequence of said second strand is the sequence of SEQ ID NO: 18 or 45.

**8.** The method of claim 7, wherein the siRNA comprises at least one modification at the 2' position of at least one ribonucleotide.

**9.** The method of claim 7, wherein said siRNA comprises at least one modification selected from the group consisting of fluoro-, methyl-, methoxyethyl- and propyl-modification.

**10.** The method of claim 9, wherein said fluoro-modification is a 2' fluoro-modification or a 2',2'-fluoro-modification.

**11.** The method of claim 7, wherein at least one pyrimidine of said siRNA is modified.

**12.** The method of claim 7, wherein both strands of said siRNA contain at least one modified nucleotide.

**13.** A vector encoding the first and/or the second strand of the double-stranded RNA of claim 1.

**14.** A host cell comprising the vector of claim 13.

**15.** The double-stranded RNA molecule of claim 1, further comprising a receptor-binding ligand attached to a 5'-end or 3'-end of said siRNA molecule.

**16.** The double-stranded RNA molecule of claim 15, wherein said receptor-binding ligand is selected from the group consisting of a cholesterol, an HBV surface antigen, a low-density lipoprotein, an HIV-1 surface antigen, an influenza virus surface antigen, an RSV surface antigen, an HPV surface antigen and a polio virus surface antigen.

60

65

**17.** The double-stranded RNA molecule of claim 1, wherein the double-stranded RNA molecule is in a combination with a second siRNA comprising a first strand and a second strand.

**18.** The composition of claim 1, wherein the sequence of 5 the second strand is the sequence of SEQ ID NO: 18 or 45.

\* \* \* \* \*